Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


The Angels Initiative

Stroke prevention


  Leukemia

  Free Subscription


Articles published in Br J Haematol

Retrieve available abstracts of 464 articles:
HTML format



Single Articles


    June 2022
  1. BRIVIO E, Cossio A, Borra D, Silvestri D, et al
    Osteonecrosis in paediatric acute lymphoblastic leukaemia: Incidence, risk factors, radiological patterns and evolution in a single-centre cohort.
    Br J Haematol. 2022;197:602-608.
    PubMed     Abstract available


  2. WALEWSKA R, Parry-Jones N, Eyre TA, Follows G, et al
    Guideline for the treatment of chronic lymphocytic leukaemia.
    Br J Haematol. 2022;197:544-557.
    PubMed    


  3. MOIA R, Gaidano G
    Updated revision of the British Society of Haematology guidelines for chronic lymphocytic leukaemia.
    Br J Haematol. 2022;197:513-514.
    PubMed    


  4. WANG QQ, Wang HF, Zhao JZ, Naranmandura H, et al
    Venetoclax for arsenic-resistant acute promyelocytic leukaemia.
    Br J Haematol. 2022;197:e58-e60.
    PubMed    


  5. MERLI P
    Treating second-relapsed/refractory first-relapsed childhood acute myeloid leukaemia: Successful salvage rather than palliation?
    Br J Haematol. 2022;197:651-652.
    PubMed     Abstract available


  6. WANG M, Lin H, Chu X, Wang Z, et al
    Identification of a recurrent fusion NUP98-RARG in acute myeloid leukaemia resembling acute promyelocytic leukaemia.
    Br J Haematol. 2022;197:e73-e78.
    PubMed    


  7. LYNGGAARD LS, Vaitkeviciene G, Langenskiold C, Lehmann AK, et al
    Asparaginase encapsulated in erythrocytes as second-line treatment in hypersensitive patients with acute lymphoblastic leukaemia.
    Br J Haematol. 2022;197:745-754.
    PubMed     Abstract available


  8. TARIQ H, Barnea Slonim L, Coty Fattal Z, Alikhan MB, et al
    Therapy-related myeloid neoplasms with normal karyotype show distinct genomic and clinical characteristics compared to their counterparts with abnormal karyotype.
    Br J Haematol. 2022;197:736-744.
    PubMed     Abstract available


  9. MORI A, Onozawa M, Tsukamoto S, Ishio T, et al
    Humoral response to mRNA-based COVID-19 vaccine in patients with myeloid malignancies.
    Br J Haematol. 2022;197:691-696.
    PubMed     Abstract available


  10. WHITE T, Kaspers G, Abrahamsson J, Arad-Cohen N, et al
    Clinical outcomes of second relapsed and refractory first relapsed paediatric AML: A retrospective study within the NOPHO-DB SHIP consortium.
    Br J Haematol. 2022;197:755-765.
    PubMed     Abstract available


    May 2022
  11. JOBSON D, McCormack CJ, Mar V, Tam C, et al
    Impact of chronic lymphocytic leukaemia on melanoma outcomes: A retrospective case-control study.
    Br J Haematol. 2022;197:320-325.
    PubMed     Abstract available


  12. TAYLOR T, Byrne J, Errico G, Clark D, et al
    Very late extramedullary relapse of acute myeloid leukaemia as prostatic myeloid sarcoma occurring 24 years post-allograft.
    Br J Haematol. 2022;197:243.
    PubMed    


  13. OLIVEIRA AF, Tansini A, Toledo T, Balceiro R, et al

    Br J Haematol. 2022;197:339-348.
    PubMed     Abstract available


  14. UJJANI C, Shadman M, Lynch RC, Tu B, et al
    The impact of B-cell-directed therapy on SARS-CoV-2 vaccine efficacy in chronic lymphocytic leukaemia.
    Br J Haematol. 2022;197:306-309.
    PubMed     Abstract available


  15. CARTWRIGHT A, Scott S, Francis S, Whitby L, et al
    Assessing the impact of the 2017 European LeukemiaNet recommendations on FLT3 allelic ratio calculation and reporting in acute myeloid leukaemia.
    Br J Haematol. 2022;197:e35-e37.
    PubMed    


  16. PETERSEN MA, Rosenberg CA, Brondum RF, Aggerholm A, et al
    Immunophenotypically defined stem cell subsets in paediatric AML are highly heterogeneous and demonstrate differences in BCL-2 expression by cytogenetic subgroups.
    Br J Haematol. 2022;197:452-466.
    PubMed     Abstract available


  17. WEI H, Zhou C, Liu B, Lin D, et al
    The prognostic factors in acute myeloid leukaemia with double-mutated CCAAT/enhancer-binding protein alpha (CEBPAdm).
    Br J Haematol. 2022;197:442-451.
    PubMed     Abstract available


  18. LEW TE, Anderson MA
    Health-related quality of life for patients with chronic lymphocytic leukaemia - A critical outcome measure in the era of highly effective therapies.
    Br J Haematol. 2022;197:394-396.
    PubMed    


  19. OERLEMANS S, Efficace F, Kieffer JM, Kyriakou C, et al
    International validation of the EORTC QLQ-CLL17 questionnaire for assessment of health-related quality of life for patients with chronic lymphocytic leukaemia.
    Br J Haematol. 2022;197:431-441.
    PubMed     Abstract available


  20. JACOBY E, Bielorai B, Hutt D, Itzhaki O, et al
    Parameters of long-term response with CD28-based CD19 chimaeric antigen receptor-modified T cells in children and young adults with B-acute lymphoblastic leukaemia.
    Br J Haematol. 2022;197:475-481.
    PubMed     Abstract available


  21. ALTER BP, Giri N, McReynolds LJ, Altintas B, et al
    Fanconi anaemia: A syndrome with distinct subgroups.
    Br J Haematol. 2022;197:467-474.
    PubMed     Abstract available


  22. YU Q, Yu D, Chen X
    Cup-shaped nuclei in acute promyelocytic leukaemia.
    Br J Haematol. 2022;197:389.
    PubMed    


    April 2022
  23. SUN C
    COVID-19 vaccine response in chronic lymphocytic leukaemia is more than just seroconversion.
    Br J Haematol. 2022;197:11-12.
    PubMed    


  24. SHEN Y, Freeman JA, Holland J, Solterbeck A, et al
    COVID-19 vaccine failure in chronic lymphocytic leukaemia and monoclonal B-lymphocytosis; humoural and cellular immunity.
    Br J Haematol. 2022;197:41-51.
    PubMed     Abstract available


  25. CLAUDIANI S, Apperley JF, Parker EL, Marchesin F, et al
    Durable humoral responses after the second anti-SARS-CoV-2 vaccine dose in chronic myeloid leukaemia patients on tyrosine kinase inhibitors.
    Br J Haematol. 2022;197:e1-e4.
    PubMed    


  26. ON S, Rath CG, Lan M, Wu B, et al
    Characterisation of infections in patients with acute myeloid leukaemia receiving venetoclax and a hypomethylating agent.
    Br J Haematol. 2022;197:63-70.
    PubMed     Abstract available


  27. GADI D, Griffith A, Wang Z, Tyekucheva S, et al
    Idelalisib reduces regulatory T cells and activates T helper 17 cell differentiation in relapsed refractory patients with chronic lymphocytic leukaemia.
    Br J Haematol. 2022;197:207-211.
    PubMed     Abstract available


  28. RECKZEH K, Estruch M, Ali M, Sogaard Helbo A, et al
    TET2 deficiency cooperates with CBFB-MYH11 to induce acute myeloid leukaemia and represents an early leukaemogenic event.
    Br J Haematol. 2022;197:201-206.
    PubMed    


  29. BRANFORD S
    BCR::ABL1 transcripts and clinical outcome - interrogating the technique.
    Br J Haematol. 2022;197:9-10.
    PubMed    


  30. DOMINY KM, Claudiani S, O'Hare M, Szydlo R, et al
    Assessment of quantitative polymerase chain reaction for BCR-ABL1 transcripts in chronic myeloid leukaemia: Are improved outcomes in patients with e14a2 transcripts an artefact of technology?
    Br J Haematol. 2022;197:52-62.
    PubMed     Abstract available


  31. VERBEEK MWC, Buracchi C, Laqua A, Nierkens S, et al
    Flow cytometric minimal residual disease assessment in B-cell precursor acute lymphoblastic leukaemia patients treated with CD19-targeted therapies - a EuroFlow study.
    Br J Haematol. 2022;197:76-81.
    PubMed     Abstract available


  32. HILLS RK
    Historical controls and venous thromboembolism prophylaxis in acute lymphoblastic leukaemia: things can only get better?
    Br J Haematol. 2022;197:e26-e27.
    PubMed    


  33. YEUNG DTO, Osborn MP, White DL
    B-cell acute lymphoblastic leukaemia: recent discoveries in molecular pathology, their prognostic significance, and a review of the current classification.
    Br J Haematol. 2022;197:13-27.
    PubMed     Abstract available


  34. TONG WH
    Does anticoagulation prophylaxis reduce the rate of venous thromboembolism in adult acute lymphoblastic leukaemia treated with asparaginase-based therapy?
    Br J Haematol. 2022;197:e24-e25.
    PubMed    


  35. JENSEN K, Oskarsson T, Lahteenmaki P, Flaegstad T, et al
    Doing less, accomplishing more for childhood ALL: response.
    Br J Haematol. 2022;197:120.
    PubMed    


    March 2022
  36. CULL G, Burger JA, Opat S, Gottlieb D, et al
    Zanubrutinib for treatment-naive and relapsed/refractory chronic lymphocytic leukaemia: long-term follow-up of the phase I/II AU-003 study.
    Br J Haematol. 2022;196:1209-1218.
    PubMed     Abstract available


  37. MORIYA K, Imamura T, Katayama S, Kaino A, et al
    The incidence of symptomatic osteonecrosis is similar between Japanese children and children in Western countries with acute lymphoblastic leukaemia treated with a Berlin-Frankfurt-Munster (BFM)95-based protocol.
    Br J Haematol. 2022;196:1257-1261.
    PubMed     Abstract available


  38. MAAS CCHM, van Klaveren D, Ector GICG, Posthuma EFM, et al
    The evolution of the loss of life expectancy in patients with chronic myeloid leukaemia: a population-based study in the Netherlands, 1989-2018.
    Br J Haematol. 2022;196:1219-1224.
    PubMed     Abstract available


  39. BARZILAI-BIRENBOIM S, Elitzur S, Nirel R, Ehrenberg M, et al
    Elevated intraocular pressure in children with acute lymphoblastic leukaemia: A prospective study.
    Br J Haematol. 2022;196:1248-1256.
    PubMed     Abstract available


  40. DILLON R, Hills RK, Burnett AK, Russell NH, et al
    Gemtuzumab ozogamicin in (KMT2A)-rearranged adult acute myeloid leukaemia (AML) in the UK Medical Research Council AML15 and AML16 trials.
    Br J Haematol. 2022;196:e50-e52.
    PubMed    


  41. WALDRON C, O'Brien D, Brophy S, Perera K, et al
    Epidemiology of chronic lymphocytic leukaemia in an Irish subpopulation with total case ascertainment: an additional tool for health economic planning.
    Br J Haematol. 2022;196:e47-e49.
    PubMed    


  42. EGNELL C, Heyman M, Jonsson OG, Raja RA, et al
    Obesity as a predictor of treatment-related toxicity in children with acute lymphoblastic leukaemia.
    Br J Haematol. 2022;196:1239-1247.
    PubMed     Abstract available


  43. GALLIPOLI P, Clark RE, Byrne J, Apperley JF, et al
    The UK SPIRIT 1 trial in newly diagnosed chronic myeloid leukaemia.
    Br J Haematol. 2022;196:e55-e57.
    PubMed    


  44. COATS T, Bean D, Basset A, Sirkis T, et al
    A novel algorithmic approach to generate consensus treatment guidelines in adult acute myeloid leukaemia.
    Br J Haematol. 2022;196:1337-1343.
    PubMed     Abstract available


  45. SALHOTRA A, Tsai NC, Zhang J, Ngo D, et al
    Venetoclax and hypomethylating agents yield high response rates and favourable transplant outcomes in patients with newly diagnosed acute myeloid leukaemia.
    Br J Haematol. 2022;196:e71-e74.
    PubMed    


  46. RUSSELL N, Hills R, Kjeldsen L, Dennis M, et al
    Treatment intensification with FLAG-Ida may improve disease control in younger patients with secondary acute myeloid leukaemia: long-term follow up of the MRC AML15 trial.
    Br J Haematol. 2022;196:1344-1347.
    PubMed     Abstract available


  47. MCCLURE BJ, Pal M, Heatley SL, Rehn J, et al
    Two novel cases of NUTM1-rearranged B-cell acute lymphoblastic leukaemia presenting with high-risk features.
    Br J Haematol. 2022;196:1407-1411.
    PubMed    


  48. LINCH DC, Hills RK, Burnett AK, Russell N, et al
    Therapy for isocitrate dehydrogenase 2 (IDH2)(R172) -mutant acute myeloid leukaemia.
    Br J Haematol. 2022;196:1348-1352.
    PubMed     Abstract available


  49. BENDE RJ, Janssen J, van Noesel CJM
    Higher-order of chronic lymphocytic leukaemia (CLL) classification: shared antigenic specificities of stereotyped B-cell receptor subsets as defined by the European Research Initiative on CLL consortium.
    Br J Haematol. 2022;196:e60-e63.
    PubMed    


  50. TAWANA K, Brown AL, Churpek JE
    Integrating germline variant assessment into routine clinical practice for myelodysplastic syndrome and acute myeloid leukaemia: current strategies and challenges.
    Br J Haematol. 2022;196:1293-1310.
    PubMed     Abstract available


    February 2022
  51. CLAUDIANI S
    Is COVID-19 less severe in CML patients than in those with other haematological cancers?
    Br J Haematol. 2022;196:471-472.
    PubMed    


  52. BRECCIA M, Abruzzese E, Accurso V, Attolico I, et al
    COVID-19 infection in chronic myeloid leukaemia after one year of the pandemic in Italy. A Campus CML report.
    Br J Haematol. 2022;196:559-565.
    PubMed     Abstract available


  53. SCHENKER C, Hirzel C, Walti LN, Zeerleder SS, et al
    Convalescent plasma and remdesivir for protracted COVID-19 in a patient with chronic lymphocytic leukaemia: a case report of late relapse after rapid initial response.
    Br J Haematol. 2022;196:e27-e29.
    PubMed    


  54. BIONDI A, Conter V, Chandy M, Ewald P, et al
    Precursor B-cell acute lymphoblastic leukaemia-a global view.
    Br J Haematol. 2022;196:530-547.
    PubMed     Abstract available


  55. SALEK C, Folber F, Fronkova E, Pecherkova P, et al
    Low levels of minimal residual disease after induction chemotherapy for BCR-ABL1-negative acute lymphoblastic leukaemia in adults are clinically relevant.
    Br J Haematol. 2022;196:706-710.
    PubMed     Abstract available


  56. DOWNES CEJ, Rehn J, Heatley SL, Yeung D, et al
    Identification of a novel GOLGA4-JAK2 fusion gene in B-cell acute lymphoblastic leukaemia.
    Br J Haematol. 2022;196:700-705.
    PubMed     Abstract available


  57. SCHWAB CJ, Murdy D, Butler E, Enshaei A, et al
    Genetic characterisation of childhood B-other-acute lymphoblastic leukaemia in UK patients by fluorescence in situ hybridisation and Multiplex Ligation-dependent Probe Amplification.
    Br J Haematol. 2022;196:753-763.
    PubMed     Abstract available


  58. TANDON S, Visser R, Astwood E, Payne J, et al
    Paediatric ambiguous lineage leukaemia with monocytic differentiation at diagnosis: case series and review of literature.
    Br J Haematol. 2022;196:e34-e39.
    PubMed    


  59. KRIEG S, Seeger H, Hofmann P, Del Prete C, et al
    Baseline creatinine predicts acute kidney injury during intensive therapy in transplant-eligible patients with acute myeloid leukaemia.
    Br J Haematol. 2022;196:781-784.
    PubMed    


  60. VOJDEMAN FJ, Helby J, Pedersen LB, Brieghel C, et al
    Chronic lymphocytic leukaemia clones are detectable decades before diagnosis.
    Br J Haematol. 2022;196:784-787.
    PubMed    


  61. HUANG W, Sundquist K, Sundquist J, Ji J, et al
    Use of dipyridamole is associated with lower risk of lymphoid neoplasms: a propensity score-matched cohort study.
    Br J Haematol. 2022;196:690-699.
    PubMed     Abstract available


  62. RIBERA J, Granada I, Morgades M, Gonzalez T, et al
    Prognostic heterogeneity of adult B-cell precursor acute lymphoblastic leukaemia patients with t(1;19)(q23;p13)/TCF3-PBX1 treated with measurable residual disease-oriented protocols.
    Br J Haematol. 2022;196:670-675.
    PubMed     Abstract available


  63. BOOTH S, Curley HM, Varnai C, Arnold R, et al
    Key findings from the UKCCMP cohort of 877 patients with haematological malignancy and COVID-19: disease control as an important factor relative to recent chemotherapy or anti-CD20 therapy.
    Br J Haematol. 2022;196:892-901.
    PubMed     Abstract available


  64. ALLAN JN, Shanafelt T, Wiestner A, Moreno C, et al
    Long-term efficacy of first-line ibrutinib treatment for chronic lymphocytic leukaemia in patients with TP53 aberrations: a pooled analysis from four clinical trials.
    Br J Haematol. 2022;196:947-953.
    PubMed     Abstract available


  65. AHMED HMM, Nimmagadda SC, Al-Matary YS, Fiori M, et al
    Dexamethasone-mediated inhibition of Notch signalling blocks the interaction of leukaemia and mesenchymal stromal cells.
    Br J Haematol. 2022;196:995-1006.
    PubMed     Abstract available


  66. SHEN Z, Zhou M, Zhang J, Chen S, et al
    Microgranular variant of acute promyelocytic leukaemia with an unusual T/myeloid immunophenotype resembling that of mixed-phenotype acute leukaemia.
    Br J Haematol. 2022;196:801.
    PubMed    


  67. ABDEL RAHMAN ZH, Parrondo RD, Heckman MG, Wieczorek M, et al
    Comparative study of therapy-related and de novo adult b-cell acute lymphoblastic leukaemia.
    Br J Haematol. 2022;196:963-968.
    PubMed     Abstract available


  68. EYRE TA, Riches JC, Patten PEM, Walewska R, et al
    Richter transformation of chronic lymphocytic leukaemia: a British Society for Haematology Good Practice Paper.
    Br J Haematol. 2022;196:864-870.
    PubMed    


    January 2022
  69. TOMOWIAK C, Leblond V, Laribi K, Baron M, et al
    Response to vaccination against SARS-CoV-2 in 168 patients with Waldenstrom macroglobulinemia: a French Innovative Leukemia Organization (FILO) study.
    Br J Haematol. 2022 Jan 14. doi: 10.1111/bjh.18055.
    PubMed    


  70. NAVILLE AS, Lazaro E, Boutin J, Prot-Leurent C, et al
    Acquired glucose 6-phosphate dehydrogenase (G6PD) deficiency in a patient with Chronic Myelomonocytic Leukemia.
    Br J Haematol. 2022 Jan 6. doi: 10.1111/bjh.18037.
    PubMed    


  71. SAULTIER P, Ninove L, Szepetowski S, Veneziano M, et al
    Monoclonal antibodies for the treatment of COVID-19 in a patient with high-risk acute leukaemia.
    Br J Haematol. 2022;196:e1-e3.
    PubMed    


  72. MARCHESI F, Pimpinelli F, Sperandio E, Papa E, et al
    The 12-week kinetics of anti-SARS-CoV-2 antibodies in different haematological cancers after vaccination with BNT162b2.
    Br J Haematol. 2022;196:362-367.
    PubMed    


  73. GASTINNE T, Le Bourgeois A, Coste-Burel M, Guillaume T, et al
    Safety and antibody response after one and/or two doses of BNT162b2 Anti-SARS-CoV-2 mRNA vaccine in patients treated by CAR T cells therapy.
    Br J Haematol. 2022;196:360-362.
    PubMed    


  74. SEVIAR D, Nyunt K, Sayer C, Wright D, et al
    Romboutsia-induced bone marrow necrosis at presentation of acute myeloid leukaemia.
    Br J Haematol. 2022;196:262.
    PubMed    


  75. YAO H, Huo L, Ping N, Liu H, et al
    Recurrent mutations in multiple components of the SWI/SNF complex in myelodysplastic syndromes and acute myeloid leukaemia.
    Br J Haematol. 2022;196:441-444.
    PubMed    


  76. KIM DDH, Kim TS, Atenafu EG, Novitzky Basso I, et al
    BCR-ABL1 transcript doubling time as a predictor for treatment-free remission failure after imatinib discontinuation in chronic myeloid leukaemia in chronic phase.
    Br J Haematol. 2022;196:136-145.
    PubMed     Abstract available


  77. LOKE J, Metzner M, Boucher R, Jackson A, et al
    Combination romidepsin and azacitidine therapy is well tolerated and clinically active in adults with high-risk acute myeloid leukaemia ineligible for intensive chemotherapy.
    Br J Haematol. 2022;196:368-373.
    PubMed     Abstract available


  78. PODVIN B, Goursaud L, Roynard P, Nibourel O, et al
    Chronic myeloid leukaemia presenting with monocytosis.
    Br J Haematol. 2022;196:8.
    PubMed    


  79. NAKAJIMA R, Matsuo T, Sumiyoshi R, Saito S, et al
    Extramedullary blast crisis in a chronic myeloid leukaemia patient after achieving a major molecular response with bosutinib.
    Br J Haematol. 2022;196:e9-e11.
    PubMed    


  80. KAYSER S, Levis MJ
    Updates on targeted therapies for acute myeloid leukaemia.
    Br J Haematol. 2022;196:316-328.
    PubMed     Abstract available


  81. MIKHAILOVA E, Roumiantseva J, Illarionova O, Lagoyko S, et al
    Strong expansion of normal CD19-negative B-cell precursors after the use of blinatumomab in the first-line therapy of acute lymphoblastic leukaemia in children.
    Br J Haematol. 2022;196:e6-e9.
    PubMed    


  82. SHANMUGANATHAN N, Branford S
    Multiplex technologies for the assessment of minimal residual disease and low-level mutation detection in leukaemia: mass spectrometry versus next-generation sequencing.
    Br J Haematol. 2022;196:19-30.
    PubMed     Abstract available


    December 2021
  83. FOX TA, Kirkwood AA, Enfield L, O'Reilly M, et al
    Low seropositivity and suboptimal neutralisation rates in patients fully vaccinated against COVID-19 with B-cell malignancies.
    Br J Haematol. 2021;195:706-709.
    PubMed    


  84. KIM HS, Lee JW, Kang D, Yu H, et al
    Characteristics of RAS pathway mutations in juvenile myelomonocytic leukaemia: a single-institution study from Korea.
    Br J Haematol. 2021;195:748-756.
    PubMed     Abstract available


  85. MINGUELA A, Salido EJ, Soto-Ramirez MF, Olga MA, et al
    Low-affinity immunoglobulin gamma Fc region receptor III-B (FcgammaRIIIB, CD16B) deficiency in patients with blood and immune system disorders.
    Br J Haematol. 2021;195:743-747.
    PubMed     Abstract available


  86. SILLA L, Valim V, Pezzi A, da Silva M, et al
    Adoptive immunotherapy with double-bright (CD56(bright) /CD16(bright) ) expanded natural killer cells in patients with relapsed or refractory acute myeloid leukaemia: a proof-of-concept study.
    Br J Haematol. 2021;195:710-721.
    PubMed     Abstract available


  87. TANG FF, Lu SY, Zhao XS, Qin YZ, et al
    PML-RARA transcript levels at the end of induction therapy are associated with prognosis in non-high-risk acute promyelocytic leukaemia with all-trans retinoic acid plus arsenic in front-line therapy: long-term follow-up of a single-centre cohort stud
    Br J Haematol. 2021;195:722-730.
    PubMed     Abstract available


    November 2021
  88. FOX CP, Ahearne MJ, Pettengell R, Dearden C, et al
    Guidelines for the management of mature T- and natural killer-cell lymphomas (excluding cutaneous T-cell lymphoma): a British Society for Haematology Guideline.
    Br J Haematol. 2021 Nov 22. doi: 10.1111/bjh.17951.
    PubMed    


  89. BENDA M, Mutschlechner B, Ulmer H, Grabher C, et al
    Serological SARS-CoV-2 antibody response, potential predictive markers and safety of BNT162b2 mRNA COVID-19 vaccine in haematological and oncological patients.
    Br J Haematol. 2021;195:523-531.
    PubMed     Abstract available


  90. SHIMONI A, Robin M, Iacobelli S, Beelen D, et al
    Allogeneic hematopoietic cell transplantation in patients with myelodysplastic syndrome using treosulfan based compared to other reduced-intensity or myeloablative conditioning regimens. A report of the chronic malignancies working party of the EBMT.
    Br J Haematol. 2021;195:417-428.
    PubMed     Abstract available


  91. HWANG J, Singh N, Braniecki M, Gok Yavuz B, et al
    Omacetaxine added to a standard acute myeloid leukaemia chemotherapy regimen reduces cellular FLIP levels, markedly increasing the incidence of eccrine hidradenitis.
    Br J Haematol. 2021;195:e138-e141.
    PubMed    


  92. SMYTH L, Blunt DN, Cheung MC
    Statins in mature B-cell lymphomas and leukaemias.
    Br J Haematol. 2021;195:490-492.
    PubMed    


  93. SOLANO DE LA ASUNCION C, Terol MJ, Saus A, Olea B, et al
    Cytomegalovirus-specific T-cell immunity and DNAemia in patients with chronic lymphocytic leukaemia undergoing treatment with ibrutinib.
    Br J Haematol. 2021;195:637-641.
    PubMed    


  94. BEGNA KH, Kittur J, Yui J, Gangat N, et al
    De novo isolated myeloid sarcoma: comparative analysis of survival in 19 consecutive cases.
    Br J Haematol. 2021;195:413-416.
    PubMed     Abstract available


  95. ZHONG ZQ, Zhuang HF, Wu SL, Zhang H, et al
    Pseudo-Chediak-Higashi inclusions in relapsed acute lymphoblastic leukaemia.
    Br J Haematol. 2021;195:300.
    PubMed    


  96. SKOU AS, Juul-Dam KL, Ommen HB, Hasle H, et al
    Peripheral blood molecular measurable residual disease is sufficient to identify patients with acute myeloid leukaemia with imminent clinical relapse.
    Br J Haematol. 2021;195:310-327.
    PubMed     Abstract available


    October 2021
  97. NOSAKA K, Kusumoto S, Nakano N, Choi I, et al
    Clinical significance of the immunoglobulin G heavy-chain repertoire in peripheral blood mononuclear cells of adult T-cell leukaemia-lymphoma patients receiving mogamulizumab.
    Br J Haematol. 2021 Oct 10. doi: 10.1111/bjh.17895.
    PubMed     Abstract available


  98. LIU M, Zhao X, Pan W, Qian Z, et al
    A novel HNRNPC-RARA fusion in acute promyelocytic leukaemia lacking PML-RARA rearrangement, sensitive to venetoclax-based therapy.
    Br J Haematol. 2021;195:e123-e128.
    PubMed    


  99. BARTRAM J, Balasch-Carulla M, Bhojaraja S, Adams S, et al
    Blinatumomab for paediatric mixed phenotype acute leukaemia.
    Br J Haematol. 2021;195:289-292.
    PubMed    


  100. EDWARDS K, Zaitseva K, Sayed U, Volpi EV, et al
    Expression patterns of CD180 in the lymph nodes of patients with chronic lymphocytic leukaemia.
    Br J Haematol. 2021;195:e131-e134.
    PubMed    


  101. TESTI AM, Mohamed S, Diverio D, Piciocchi A, et al
    Outcome of relapsed/refractory acute promyelocytic leukaemia in children, adolescents and young adult patients - a 25-year Italian experience.
    Br J Haematol. 2021;195:278-283.
    PubMed    


  102. BEZDEKOVA R, Jelinek T, Kralova R, Stork M, et al
    Necessity of flow cytometry assessment of circulating plasma cells and its connection with clinical characteristics of primary and secondary plasma cell leukaemia.
    Br J Haematol. 2021;195:95-107.
    PubMed     Abstract available


  103. GOULD C, Lickiss J, Kankanige Y, Yerneni S, et al
    Characterisation of immune checkpoints in Richter syndrome identifies LAG3 as a potential therapeutic target.
    Br J Haematol. 2021;195:113-118.
    PubMed     Abstract available


  104. THASTRUP M, Marquart HV, Levinsen M, Modvig S, et al
    Flow cytometric analysis of cerebrospinal fluid improves detection of leukaemic blasts in infants with acute lymphoblastic leukaemia.
    Br J Haematol. 2021;195:119-122.
    PubMed     Abstract available


  105. O'CONNOR D, Loke J, Brown M, Stanworth SJ, et al
    Non-pharmacological supportive-care interventions in acute myeloid leukaemia: a review of randomised controlled trials.
    Br J Haematol. 2021;195:e97-e113.
    PubMed    


  106. MAENG CV, Ostgard LSG, Christiansen CF, Liu KD, et al
    Changes in intensive care unit admission rates, organ support, and mortality in patients with acute myeloid leukaemia over a 12-year period: a Danish nationwide cohort study.
    Br J Haematol. 2021;195:137-140.
    PubMed    


    September 2021
  107. COOK LBM
    Adult T-cell leukaemia/lymphoma and the trouble with TP53.
    Br J Haematol. 2021 Sep 9. doi: 10.1111/bjh.17830.
    PubMed    


  108. CHATTERJEE G, Sriram H, Ghogale S, Deshpande N, et al
    Mimics and artefacts of measurable residual disease in a highly sensitive multicolour flow cytometry assay for B-lymphoblastic leukaemia/lymphoma: critical consideration for analysis of measurable residual disease.
    Br J Haematol. 2021 Sep 2. doi: 10.1111/bjh.17801.
    PubMed     Abstract available


  109. CHOWDHURY O, Bruguier H, Mallett G, Sousos N, et al
    Impaired antibody response to COVID-19 vaccination in patients with chronic myeloid neoplasms.
    Br J Haematol. 2021;194:1010-1015.
    PubMed    


  110. HARRINGTON P, Doores KJ, Radia D, O'Reilly A, et al
    Single dose of BNT162b2 mRNA vaccine against severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) induces neutralising antibody and polyfunctional T-cell responses in patients with chronic myeloid leukaemia.
    Br J Haematol. 2021;194:999-1006.
    PubMed     Abstract available



  111. A special issue on modern genomics in diagnostic haematology.
    Br J Haematol. 2021;194:801-802.
    PubMed    


  112. KUIPER RP, Hoogeveen PG, Bladergroen R, van Dijk F, et al
    Minimal residual disease (MRD) detection in acute lymphoblastic leukaemia based on fusion genes and genomic deletions: towards MRD for all.
    Br J Haematol. 2021;194:888-892.
    PubMed     Abstract available


  113. KHAN M, Roddy JT, Hernandez JR, Bursch K, et al
    Revisiting biochemistry: severe euglycemic ketoacidosis in the setting of IDH-inhibitor therapy for AML.
    Br J Haematol. 2021;194:1083-1085.
    PubMed    


  114. RASCHE A, Mason EF, Strickland SA, Byrne M, et al
    Isocitrate dehydrogenase inhibitor-driven differentiation may resemble secondary graft failure in post-allogeneic haematopoietic cell transplantation relapsed acute myeloid leukaemia.
    Br J Haematol. 2021;194:927-931.
    PubMed    


  115. ALCALDE-MELLADO P, Franco-Macias E, Morales-Camacho RM, Caballero-Velazquez T, et al
    Auer rod-like inclusions in cerebrospinal fluid in accelerated phase chronic lymphocytic leukaemia.
    Br J Haematol. 2021;194:946.
    PubMed    


    August 2021
  116. SAKAMOTO Y, Ishida T, Masaki A, Murase T, et al
    Clinical significance of TP53 mutations in adult T-cell leukemia/lymphoma.
    Br J Haematol. 2021 Aug 17. doi: 10.1111/bjh.17749.
    PubMed     Abstract available


  117. FANG H, Wang W, El Hussein S, Morita K, et al
    B-cell lymphoma/leukaemia 11B (BCL11B) expression status helps distinguish early T-cell precursor acute lymphoblastic leukaemia/lymphoma (ETP-ALL/LBL) from other subtypes of T-cell ALL/LBL.
    Br J Haematol. 2021 Aug 16. doi: 10.1111/bjh.17681.
    PubMed     Abstract available


  118. HENRY A, Bracquemart C, Naguib D, Chantepie S, et al
    Does eventually NPM1 mutation in blast phase chronic myeloid leukemia (BP-CML) exist? That is the question.
    Br J Haematol. 2021 Aug 15. doi: 10.1111/bjh.17761.
    PubMed    


  119. PATEL PA, Lapp SA, Grubbs G, Edara VV, et al
    Immune responses and therapeutic challenges in paediatric patients with new-onset acute myeloid leukaemia and concomitant COVID-19.
    Br J Haematol. 2021;194:549-553.
    PubMed    


  120. LUCCHINI G, Furness C, Lawson S, Gibson B, et al
    COVID-19 infection in paediatric recipients of allogeneic stem cell transplantation: the UK experience.
    Br J Haematol. 2021;194:e74-e77.
    PubMed    


  121. YEOH AEJ, Oh BL, Ariffin H
    Doing less, accomplishing more for childhood acute lymphoblastic leukaemia (ALL).
    Br J Haematol. 2021;194:661-662.
    PubMed    


  122. NOURA M, Morita K, Kiyose H, Okuno Y, et al
    Albendazole induces the terminal differentiation of acute myeloid leukaemia cells to monocytes by stimulating the Kruppel-like factor 4-dihydropyrimidinase-like 2A (KLF4-DPYSL2A) axis.
    Br J Haematol. 2021;194:598-603.
    PubMed     Abstract available


  123. RAMDENY PS, Mullanfroze K, de Lorenzo P, Grazia Valsecchi M, et al
    Infant T-cell acute lymphoblastic leukaemia with t(6;7) (TCRB-MYB) translocation.
    Br J Haematol. 2021;194:613-616.
    PubMed     Abstract available


  124. ROMZOVA M, Smitalova D, Hynst J, Tom N, et al
    Hierarchical distribution of somatic variants in newly diagnosed chronic myeloid leukaemia at diagnosis and early follow-up.
    Br J Haematol. 2021;194:604-612.
    PubMed     Abstract available


  125. MASLAH N, Diawara Y, Sebert M, Giraudier S, et al
    In vitro assessment of the sensitivity to APR-246 + azacitidine combination predicts response to this combination in myelodysplastic/acute myeloid leukaemia patients.
    Br J Haematol. 2021;194:e77-e79.
    PubMed    


  126. JENSEN KS, Oskarsson T, Lahteenmaki PM, Flaegstad T, et al
    Detection mode of childhood acute lymphoblastic leukaemia relapse and its effect on survival: a Nordic population-based cohort study.
    Br J Haematol. 2021;194:734-744.
    PubMed     Abstract available


  127. CORNEAU A, Parizot C, Cherai M, Todesco E, et al
    Mass Cytometry: a robust platform for the comprehensive immunomonitoring of CAR-T-cell therapies.
    Br J Haematol. 2021;194:788-792.
    PubMed    


  128. ALLSUP D, Howard D, Emmerson J, Hockaday A, et al
    COSMIC, chemotherapy plus ofatumumab at standard or mega-dose in chronic lymphocytic leukaemia, a phase II randomised study.
    Br J Haematol. 2021;194:646-650.
    PubMed    


  129. LOBO-OLMEDO A, Roldan Galiacho V, Arzuaga-Mendez J, Ancin I, et al
    Acute megakaryoblastic leukaemia with erythrophagocytosis.
    Br J Haematol. 2021;194:658.
    PubMed    


    July 2021
  130. BRANVALL E, Ekberg S, Eloranta S, Wasterlid T, et al
    Statin use and survival in 16 098 patients with non-Hodgkin lymphoma or chronic lymphocytic leukaemia treated in the rituximab era.
    Br J Haematol. 2021 Jul 31. doi: 10.1111/bjh.17733.
    PubMed     Abstract available


  131. MOIA R, Favini C, Ferri V, Forestieri G, et al
    Multiregional sequencing and circulating tumour DNA analysis provide complementary approaches for comprehensive disease profiling of small lymphocytic lymphoma.
    Br J Haematol. 2021 Jul 22. doi: 10.1111/bjh.17718.
    PubMed     Abstract available


  132. HEHLMANN R
    What is the right dosage of dasatinib for treating chronic myeloid leukaemia?
    Br J Haematol. 2021;194:234.
    PubMed    


  133. ROUSSELOT P, Mollica L, Guilhot J, Guerci A, et al
    Dasatinib dose optimisation based on therapeutic drug monitoring reduces pleural effusion rates in chronic myeloid leukaemia patients.
    Br J Haematol. 2021;194:393-402.
    PubMed     Abstract available


  134. NAKAMURA M, Arai Y, Hirabayashi S, Kondo T, et al
    Residual disease is a strong prognostic marker in patients with acute lymphoblastic leukaemia with chemotherapy-refractory or relapsed disease prior to allogeneic stem cell transplantation.
    Br J Haematol. 2021;194:403-413.
    PubMed     Abstract available


  135. COMONT T, Meunier M, Cherait A, Santana C, et al
    Eltrombopag for myelodysplastic syndromes or chronic myelomonocytic leukaemia with no excess blasts and thrombocytopenia: a French multicentre retrospective real-life study.
    Br J Haematol. 2021;194:336-343.
    PubMed     Abstract available


  136. WIERNIK PH, Sun Z, Cripe LD, Rowe JM, et al
    Prognostic effect of gender on outcome of treatment for adults with acute myeloid leukaemia.
    Br J Haematol. 2021;194:309-318.
    PubMed     Abstract available


  137. ROEKER LE, Thompson MC, Mato AR
    Searching for a home: phosphoinositide 3-kinase inhibitors for chronic lymphocytic leukaemia in modern clinical practice.
    Br J Haematol. 2021;194:9-10.
    PubMed    


  138. MULRONEY CM, Abid MB, Bashey A, Chemaly RF, et al
    Incidence and impact of community respiratory viral infections in post-transplant cyclophosphamide-based graft-versus-host disease prophylaxis and haploidentical stem cell transplantation.
    Br J Haematol. 2021;194:145-157.
    PubMed     Abstract available


  139. EYRE TA, Preston G, Kagdi H, Islam A, et al
    A retrospective observational study to evaluate the clinical outcomes and routine management of patients with chronic lymphocytic leukaemia treated with idelalisib and rituximab in the UK and Ireland (RETRO-idel).
    Br J Haematol. 2021;194:69-77.
    PubMed     Abstract available


  140. SASAKI K, Tsujimoto S, Miyake M, Uchiyama Y, et al
    Droplet digital polymerase chain reaction assay for the detection of the minor clone of KIT D816V in paediatric acute myeloid leukaemia especially showing RUNX1-RUNX1T1 transcripts.
    Br J Haematol. 2021;194:414-422.
    PubMed     Abstract available


  141. SCOTT S, Cartwright A, Francis S, Whitby L, et al
    Assessment of droplet digital polymerase chain reaction for measuring BCR-ABL1 in chronic myeloid leukaemia in an international interlaboratory study.
    Br J Haematol. 2021;194:53-60.
    PubMed     Abstract available


  142. RADICH J
    Building a better mousetrap for accurate and sensitive polymerase chain reaction.
    Br J Haematol. 2021;194:11-13.
    PubMed    


  143. SASSEN SDT, Mathot RAA, Pieters R, de Haas V, et al
    Evaluation of the pharmacokinetics of prednisolone in paediatric patients with acute lymphoblastic leukaemia treated according to Dutch Childhood Oncology Group protocols and its relation to treatment response.
    Br J Haematol. 2021;194:423-432.
    PubMed     Abstract available


  144. KOUKOULIAS K, Papadopoulou A, Kouimtzidis A, Papayanni PG, et al
    Non-transplantable cord blood units as a source for adoptive immunotherapy of leukaemia and a paradigm of circular economy in medicine.
    Br J Haematol. 2021;194:158-167.
    PubMed     Abstract available


  145. BODOR C, Kotmayer L, Laszlo T, Takacs F, et al
    Screening and monitoring of the BTK(C481S) mutation in a real-world cohort of patients with relapsed/refractory chronic lymphocytic leukaemia during ibrutinib therapy.
    Br J Haematol. 2021;194:355-364.
    PubMed     Abstract available


  146. MICHALOWSKI MB, Cecconello DK, Lins MM, Carvalho MDPSS, et al
    Influence of different asparaginase formulations in the prognosis of children with acute lymphocytic leukaemia in Brazil: a multicentre, retrospective controlled study.
    Br J Haematol. 2021;194:168-173.
    PubMed     Abstract available


  147. ZHAO Y, McCracken J, Rehder C, Wang E, et al
    Biclonal evolution of chronic lymphocytic leukaemia.
    Br J Haematol. 2021;194:e64-e66.
    PubMed    


  148. CHERNG HJ, Jammal N, Paul S, Wang X, et al
    Clinical and molecular characteristics and treatment patterns of adolescent and young adult patients with chronic lymphocytic leukaemia.
    Br J Haematol. 2021;194:61-68.
    PubMed     Abstract available


  149. DENNIS M, Burnett A, Hills R, Thomas I, et al
    A randomised evaluation of low-dose cytosine arabinoside (ara-C) plus tosedostat versus low-dose ara-C in older patients with acute myeloid leukaemia: results of the LI-1 trial.
    Br J Haematol. 2021;194:298-308.
    PubMed     Abstract available


  150. POCOCK R, Farah N, Richardson SE, Mansour MR, et al
    Current and emerging therapeutic approaches for T-cell acute lymphoblastic leukaemia.
    Br J Haematol. 2021;194:28-43.
    PubMed     Abstract available


  151. ASSANTO GM, Riemma C, Malaspina F, Perrone S, et al
    The current role of interferon in hairy cell leukaemia: clinical and molecular aspects.
    Br J Haematol. 2021;194:78-82.
    PubMed     Abstract available


  152. POPOV A, Fominikh V, Mikhailova E, Shelikhova L, et al
    Blinatumomab following haematopoietic stem cell transplantation - a novel approach for the treatment of acute lymphoblastic leukaemia in infants.
    Br J Haematol. 2021;194:174-178.
    PubMed     Abstract available


  153. KOLLA BC, Halim NAA, Cao Q, Sachs Z, et al
    High risk of relapse with intermediate dose cytarabine for consolidation in young favourable-risk acute myeloid leukaemia patients following induction with 7+3: a retrospective multicentre analysis and critical review of the literature.
    Br J Haematol. 2021;194:140-144.
    PubMed     Abstract available


  154. HSU H, Roncolato F, Lee SH
    Lysosomal acid lipase deficiency diagnosed in a patient presenting with acute myeloid leukaemia.
    Br J Haematol. 2021;194:228.
    PubMed    


  155. SHACKLETON L, McCarthy J, Mykytiv V
    Extramedullary pericardial haematopoiesis as a presenting feature of chronic myeloid leukaemia.
    Br J Haematol. 2021;194:7.
    PubMed    


    June 2021
  156. OSTERGAARD J, Jonart LM, Ebadi M, Koppenhafer SL, et al
    Preclinical efficacy of prexasertib in acute lymphoblastic leukemia.
    Br J Haematol. 2021 Jun 7. doi: 10.1111/bjh.17610.
    PubMed    


  157. KARANTANOS T, Gondek LP, Varadhan R, Moliterno AR, et al
    Gender-related differences in the outcomes and genomic landscape of patients with myelodysplastic syndrome/myeloproliferative neoplasm overlap syndromes.
    Br J Haematol. 2021;193:1142-1150.
    PubMed     Abstract available


  158. XU R, Huang X, Li C, Deng C, et al
    Bone marrow mesenchymal stromal cells in chronic myelomonocytic leukaemia: overactivated WNT/beta-catenin signalling by parallel RNA sequencing and dysfunctional phenotypes.
    Br J Haematol. 2021;193:928-940.
    PubMed     Abstract available


  159. MOSKORZ W, Cosmovici C, Jager PS, Cadeddu RP, et al
    Myelodysplastic syndrome patients display alterations in their immune status reflected by increased PD-L1-expressing stem cells and highly dynamic exhausted T-cell frequencies.
    Br J Haematol. 2021;193:941-945.
    PubMed     Abstract available


  160. CAO H, Neerincx A, de Bono B, Lakner U, et al
    Sialic acid-binding immunoglobulin-like lectin (Sigelac)-15 is a rapidly internalised cell-surface antigen expressed by acute myeloid leukaemia cells.
    Br J Haematol. 2021;193:946-950.
    PubMed     Abstract available


  161. DHOLARIA B, Savani BN, Huang XJ, Nagler A, et al
    The evolving role of allogeneic haematopoietic cell transplantation in the era of chimaeric antigen receptor T-cell therapy.
    Br J Haematol. 2021;193:1060-1075.
    PubMed     Abstract available


  162. NISHIMURA A, Naruto T, Miyamoto S, Grigg A, et al
    Genomics analysis of leukaemia predisposition in X-linked agammaglobulinaemia.
    Br J Haematol. 2021;193:1277-1281.
    PubMed    


  163. VAN DE GEER A, Zandstra J, Tanck MWT, Nur E, et al
    Biomarkers to predict infection and infection-related complications during chemotherapy-induced neutropenia in acute myeloid leukaemia: a pilot study.
    Br J Haematol. 2021;193:1008-1012.
    PubMed    


  164. SHAH MV, Saliba RM, Varma A, Ciurea SO, et al
    Allogeneic stem cell transplant for patients with myeloproliferative neoplasms in blast phase: improving outcomes in the recent era.
    Br J Haematol. 2021;193:1004-1008.
    PubMed    


  165. FLYGT H, Sandin F, Dahlen T, Dremaine A, et al
    Successful tyrosine kinase inhibitor discontinuation outside clinical trials - data from the population-based Swedish chronic myeloid leukaemia registry.
    Br J Haematol. 2021;193:915-921.
    PubMed     Abstract available


  166. WANG H, Zhou Y, Huang X, Zhang Y, et al
    Minimal residual disease level determined by flow cytometry provides reliable risk stratification in adults with T-cell acute lymphoblastic leukaemia.
    Br J Haematol. 2021;193:1096-1104.
    PubMed     Abstract available


  167. CREUZET E, Nourrisson C, Chaleteix C, Poirier P, et al
    Cerebral aspergillosis in a patient on ibrutinib therapy.
    Br J Haematol. 2021;193:1025.
    PubMed    


  168. DANDER E, Fallati A, Gulic T, Pagni F, et al
    Monocyte-macrophage polarization and recruitment pathways in the tumour microenvironment of B-cell acute lymphoblastic leukaemia.
    Br J Haematol. 2021;193:1157-1171.
    PubMed     Abstract available


  169. TSAUR G, Popov A, Riger T, Kustanovich A, et al
    Prognostic value of minimal residual disease measured by fusion-gene transcript in infants with KMT2A-rearranged acute lymphoblastic leukaemia treated according to the MLL-Baby protocol.
    Br J Haematol. 2021;193:1151-1156.
    PubMed     Abstract available


  170. BRIVIO E, Chantrain CF, Gruber TA, Thano A, et al
    Inotuzumab ozogamicin in infants and young children with relapsed or refractory acute lymphoblastic leukaemia: a case series.
    Br J Haematol. 2021;193:1172-1177.
    PubMed     Abstract available


  171. BRAS AE, Osmani Z, de Haas V, Jongen-Lavrencic M, et al
    Standardised immunophenotypic analysis of myeloperoxidase in acute leukaemia.
    Br J Haematol. 2021;193:922-927.
    PubMed     Abstract available


    May 2021
  172. CHANDER G, Nikolousis E, Kanellopoulos A
    Human papilloma virus (HPV)-associated lesions in a post-bone marrow transplant patient responding to HPV vaccination.
    Br J Haematol. 2021 May 2. doi: 10.1111/bjh.17514.
    PubMed    


  173. ROSS DM
    How much imatinib is enough?
    Br J Haematol. 2021;193:699-700.
    PubMed    


  174. KIM DDH, Novitzky-Basso I, Kim TS, Atenafu EG, et al
    Optimal duration of imatinib treatment/deep molecular response for treatment-free remission after imatinib discontinuation from a Canadian tyrosine kinase inhibitor discontinuation trial.
    Br J Haematol. 2021;193:779-791.
    PubMed     Abstract available


  175. KHARFAN-DABAJA MA, Labopin M, Brissot E, Kroger N, et al
    Second allogeneic haematopoietic cell transplantation using HLA-matched unrelated versus T-cell replete haploidentical donor and survival in relapsed acute myeloid leukaemia.
    Br J Haematol. 2021;193:592-601.
    PubMed     Abstract available


  176. AOKI K, Kurashige M, Ichii M, Higaki K, et al
    Identification of CXCL12-abundant reticular cells in human adult bone marrow.
    Br J Haematol. 2021;193:659-668.
    PubMed     Abstract available


  177. MIKHAILOVA E, Semchenkova A, Illarionova O, Kashpor S, et al
    Relative expansion of CD19-negative very-early normal B-cell precursors in children with acute lymphoblastic leukaemia after CD19 targeting by blinatumomab and CAR-T cell therapy: implications for flow cytometric detection of minimal residual disease.
    Br J Haematol. 2021;193:602-612.
    PubMed     Abstract available


  178. SEMBILL S, Gohring G, Schirmer E, Lutterloh F, et al
    Paediatric chronic myeloid leukaemia presenting in de novo or secondary blast phase - a comparison of clinical and genetic characteristics.
    Br J Haematol. 2021;193:613-618.
    PubMed     Abstract available


  179. DE MIGUEL SANCHEZ C, Robles de Castro D, Pison Herrero C, Perez Persona E, et al
    Primary plasma cell leukaemia presenting with flower-shaped nuclei.
    Br J Haematol. 2021;193:689.
    PubMed    


  180. CHEN D, Chen W
    Salmon-coloured granules in residual acute myeloid leukaemia with t(8;21)(q22;q22.1); RUNX1-RUNX1T1.
    Br J Haematol. 2021;193:691.
    PubMed    


  181. NOY-LOTAN S, Krasnov T, Dgany O, Jeison M, et al
    Incorporation of somatic panels for the detection of haematopoietic transformation in children and young adults with leukaemia predisposition syndromes and with acquired cytopenias.
    Br J Haematol. 2021;193:570-580.
    PubMed     Abstract available


  182. HJORT JAKOBSEN L, Stidsholt Roug A, Kiesbye Ovlisen A, Werenberg Marcher C, et al
    Temporal changes in survival among adult patients with acute myeloid leukaemia in the period 2000-2016: a Danish population-based study.
    Br J Haematol. 2021;193:482-487.
    PubMed     Abstract available


  183. SMOLEJ L
    Skipping a step: what happened to the design of randomized clinical trials in chronic lymphocytic leukaemia?
    Br J Haematol. 2021;193:723-726.
    PubMed     Abstract available


    April 2021
  184. DO C, Best OG, Thurgood L, Hotinski A, et al
    Insight into del17p low-frequency subclones in chronic lymphocytic leukaemia (CLL): data from the Australasian Leukaemia and Lymphoma Group (ALLG)/CLL Australian Research Consortium (CLLARC) CLL5 trial.
    Br J Haematol. 2021 Apr 13. doi: 10.1111/bjh.17394.
    PubMed     Abstract available


  185. ZHENG J, Wu S, Hu Y, Gao L, et al
    Management of ETV6-ABL1-positive childhood acute lymphoblastic leukaemia: report of two cases, a literature review and a call for action.
    Br J Haematol. 2021;193:197-200.
    PubMed    


  186. GANESAN P, Jain H, Bagal B, Subramanian PG, et al
    Outcomes in adolescent and young adult acute lymphoblastic leukaemia: a report from the Indian Acute Leukaemia Research Database (INwARD) of the Hematology Cancer Consortium (HCC).
    Br J Haematol. 2021;193:e1-e4.
    PubMed    


  187. FITTER S, Bradey AL, Kok CH, Noll JE, et al
    CKLF and IL1B transcript levels at diagnosis are predictive of relapse in children with pre-B-cell acute lymphoblastic leukaemia.
    Br J Haematol. 2021;193:171-175.
    PubMed     Abstract available


  188. TROUSSARD X, Grever MR
    The revised guidelines for the diagnosis and management of hairy cell leukaemia and the hairy cell leukaemia variant.
    Br J Haematol. 2021;193:11-14.
    PubMed    


  189. GAILLLARD B, Cornillet-Lefebvre P, Le QH, Maloum K, et al
    Clinical and biological features of B-cell neoplasms with CDK6 translocations: an association with a subgroup of splenic marginal zone lymphomas displaying frequent CD5 expression, prolymphocytic cells, and TP53 abnormalities.
    Br J Haematol. 2021;193:72-82.
    PubMed     Abstract available


  190. SMOLEJ L, Turcsanyi P, Kubova Z, Zuchnicka J, et al
    External validation of International Prognostic Score for asymptomatic early stage chronic lymphocytic leukaemia and proposal of an alternative score.
    Br J Haematol. 2021;193:133-137.
    PubMed     Abstract available


  191. DANILOV AV, Persky DO
    Incorporating acalabrutinib, a selective next-generation Bruton tyrosine kinase inhibitor, into clinical practice for the treatment of haematological malignancies.
    Br J Haematol. 2021;193:15-25.
    PubMed     Abstract available


  192. RASTOGI N, Baker S, Man S, Uger RA, et al
    Use of an anti-CD200-blocking antibody improves immune responses to AML in vitro and in vivo.
    Br J Haematol. 2021;193:155-159.
    PubMed     Abstract available


  193. GURNARI C, Breccia M, Di Giuliano F, Scalzulli E, et al
    Early intracranial haemorrhages in acute promyelocytic leukaemia: analysis of neuroradiological and clinico-biological parameters.
    Br J Haematol. 2021;193:129-132.
    PubMed     Abstract available


  194. STILGENBAUER S, Bosch F, Ilhan O, Kisro J, et al
    Safety and efficacy of obinutuzumab alone or with chemotherapy in previously untreated or relapsed/refractory chronic lymphocytic leukaemia patients: Final analysis of the Phase IIIb GREEN study.
    Br J Haematol. 2021;193:325-338.
    PubMed     Abstract available


  195. DA CUNHA-BANG C, Rostgaard K, Andersen MA, Rotbain EC, et al
    Risk of new malignancies among patients with CLL treated with chemotherapy: results of a Danish population-based study.
    Br J Haematol. 2021;193:339-345.
    PubMed     Abstract available


  196. SOVERINI S, Martelli M, Bavaro L, De Benedittis C, et al
    Next-generation sequencing improves BCR-ABL1 mutation detection in Philadelphia chromosome-positive acute lymphoblastic leukaemia.
    Br J Haematol. 2021;193:271-279.
    PubMed     Abstract available


  197. CLAUDIANI S, Apperley JF, Szydlo R, Khan A, et al
    TKI dose reduction can effectively maintain major molecular remission in patients with chronic myeloid leukaemia.
    Br J Haematol. 2021;193:346-355.
    PubMed     Abstract available


  198. DILLON R, Potter N, Freeman S, Russell N, et al
    How we use molecular minimal residual disease (MRD) testing in acute myeloid leukaemia (AML).
    Br J Haematol. 2021;193:231-244.
    PubMed     Abstract available


    March 2021
  199. HASSERJIAN RP
    Flow cytometry reveals the nuances of clonal haematopoiesis.
    Br J Haematol. 2021;192:949-950.
    PubMed    


  200. BECKER MW, Angelucci E
    A large co-operative biological and clinical study to better understand and improve treatment of the rare t(8;16)(p11;p13) acute myeloid leukaemia.
    Br J Haematol. 2021;192:800-802.
    PubMed    


  201. LOGHAVI S, DiNardo CD, Furudate K, Takahashi K, et al
    Flow cytometric immunophenotypic alterations of persistent clonal haematopoiesis in remission bone marrows of patients with NPM1-mutated acute myeloid leukaemia.
    Br J Haematol. 2021;192:1054-1063.
    PubMed     Abstract available


  202. SCHLIEMANN C, Kessler T, Berdel AF, Hemmerle T, et al
    Phase I study of F16IL2 antibody-cytokine fusion with very low-dose araC in acute myeloid leukaemia relapse after allogeneic stem cell transplantation.
    Br J Haematol. 2021;192:e148-e151.
    PubMed    


  203. FERRARI A, Ghelli Luserna Di Rora A, Domizio C, Papayannidis C, et al
    Rearrangements of ATP5L-KMT2A in acute lymphoblastic leukaemia.
    Br J Haematol. 2021;192:e139-e144.
    PubMed    


  204. RIGOLIN GM, Saccenti E, Melandri A, Cavallari M, et al
    In chronic lymphocytic leukaemia, SLAMF1 deregulation is associated with genomic complexity and independently predicts a worse outcome.
    Br J Haematol. 2021;192:1068-1072.
    PubMed     Abstract available


  205. TIONG IS, Dillon R, Ivey A, Teh TC, et al
    Venetoclax induces rapid elimination of NPM1 mutant measurable residual disease in combination with low-intensity chemotherapy in acute myeloid leukaemia.
    Br J Haematol. 2021;192:1026-1030.
    PubMed     Abstract available


  206. QU S, Li B, Qin T, Xu Z, et al
    Molecular and clinical features of myeloid neoplasms with somatic DDX41 mutations.
    Br J Haematol. 2021;192:1006-1010.
    PubMed     Abstract available


  207. LUNDIN-STROM KB, Biloglav A, Lazarevic V, Behrendtz M, et al
    Parental origin of monosomy 7 in acute leukaemia.
    Br J Haematol. 2021;192:e132-e135.
    PubMed    


  208. KAYSER S, Hills RK, Langova R, Kramer M, et al
    Characteristics and outcome of patients with acute myeloid leukaemia and t(8;16)(p11;p13): results from an International Collaborative Study.
    Br J Haematol. 2021;192:832-842.
    PubMed     Abstract available


    February 2021
  209. SMOLEJ L, Brychtova Y, Cmunt E, Doubek M, et al
    Low-dose fludarabine and cyclophosphamide combined with rituximab in the first-line treatment of elderly/comorbid patients with chronic lymphocytic leukaemia/small lymphocytic lymphoma (CLL/SLL): long-term results of project Q-lite by the Czech CLL St
    Br J Haematol. 2021 Feb 22. doi: 10.1111/bjh.17373.
    PubMed     Abstract available


  210. WOUTERS Y, Nevejan L, Louwagie A, Devos H, et al
    Efficacy of ruxolitinib in B-lymphoblastic leukaemia with the PCM1-JAK2 fusion gene.
    Br J Haematol. 2021;192:e112-e115.
    PubMed    


  211. WANG J
    Leukaemia blues - an unusual presentation of leukaemia cutis.
    Br J Haematol. 2021;192:676.
    PubMed    


  212. GORDON MJ, Huang J, Chan RJ, Bhargava P, et al
    Medical comorbidities in patients with chronic lymphocytic leukaemia treated with idelalisib: analysis of two large randomised clinical trials.
    Br J Haematol. 2021;192:720-728.
    PubMed     Abstract available


  213. EGHOLM GJ, Andersen MA, Andersen CL, Frederiksen H, et al
    Abnormal eosinophil count at CLL diagnosis correlates with shorter treatment free survival.
    Br J Haematol. 2021;192:e81-e84.
    PubMed    


  214. HOTINSKI AK, Best OG, Thurgood LA, Lower KM, et al
    A biclonal case of chronic lymphocytic leukaemia with discordant mutational status of the immunoglobulin heavy chain variable region and bimodal CD49d expression.
    Br J Haematol. 2021;192:e77-e81.
    PubMed    


  215. ALI AM, Cooper J, Walker A, Jones D, et al
    Adult-onset acute myeloid leukaemia in a patient with germline mutation of CBL.
    Br J Haematol. 2021;192:665-667.
    PubMed    


  216. BRAUNSTEIN Z, Mishra A, Staub A, Freud AG, et al
    Clinical outcomes in T-cell large granular lymphocytic leukaemia: prognostic factors and treatment response.
    Br J Haematol. 2021;192:484-493.
    PubMed     Abstract available


  217. FLOETH M, Elges S, Gerss J, Schwoppe C, et al
    Low-density lipoprotein receptor (LDLR) is an independent adverse prognostic factor in acute myeloid leukaemia.
    Br J Haematol. 2021;192:494-503.
    PubMed     Abstract available


  218. MORENO BERGGREN D, Kjellander M, Backlund E, Engvall M, et al
    Prognostic scoring systems and comorbidities in chronic myelomonocytic leukaemia: a nationwide population-based study.
    Br J Haematol. 2021;192:474-483.
    PubMed     Abstract available


  219. DIAMANTI P, Ede BC, Dace PE, Barendt WJ, et al
    Investigating the response of paediatric leukaemia-propagating cells to BCL-2 inhibitors.
    Br J Haematol. 2021;192:577-588.
    PubMed     Abstract available


    January 2021
  220. AKINOSOGLOU K, Paliogianni F, Spyridonidis A, Symeonidis A, et al
    SARS-CoV-2 persistence and non-protective immunity in infected haematological patients.
    Br J Haematol. 2021;192:e51-e54.
    PubMed    


  221. BRECCIA M
    Autologous stem cell transplantation finds a place in acute promyelocytic leukaemia.
    Br J Haematol. 2021;192:237-238.
    PubMed    


  222. ROSS DM, Hughes TP
    Counterpoint: There is a best duration of deep molecular response for treatment-free remission, but it is patient-specific, and that is the challenge.
    Br J Haematol. 2021;192:24-27.
    PubMed     Abstract available


  223. KARAGIANNIS P, Alsdorf W, Tallarek AC, Blohm ME, et al
    Treatment of refractory acute myeloid leukaemia during pregnancy with venetoclax, high-dose cytarabine and mitoxantrone.
    Br J Haematol. 2021;192:e60-e63.
    PubMed    


  224. FOUZIA NA, Sharma V, Ganesan S, Palani HK, et al
    Management of relapse in acute promyelocytic leukaemia treated with up-front arsenic trioxide-based regimens.
    Br J Haematol. 2021;192:292-299.
    PubMed     Abstract available


  225. JIN W, Chen L, Liu Y, Chen Q, et al
    A novel KMT2A-USO1 fusion gene-induced de novo secondary acute myeloid leukaemia in a patient initially diagnosed with acute promyelocytic leukaemia.
    Br J Haematol. 2021;192:e32-e36.
    PubMed    


  226. OTTAVIANO G, Baird S, Bonney D, Connor P, et al
    The role of immunotherapy in relapse/refractory precursor-B acute lymphoblastic leukaemia: real-life UK/Ireland experience in children and young adults.
    Br J Haematol. 2021;192:e42-e44.
    PubMed    


  227. CAVALLINI C, Galasso M, Pozza ED, Chignola R, et al
    Effects of CD20 antibodies and kinase inhibitors on B-cell receptor signalling and survival of chronic lymphocytic leukaemia cells.
    Br J Haematol. 2021;192:333-342.
    PubMed     Abstract available


  228. GALE RP, Saglio G
    Point: Is there a best duration of deep molecular response to achieve therapy-free remission in chronic myeloid leukaemia?
    Br J Haematol. 2021;192:22-23.
    PubMed    


  229. MATSUO H, Wakita T, Hiramatsu H, Ohmori K, et al
    Blast cells in acute megakaryoblastic leukaemia with Down syndrome are characterized by low CLEC12A expression.
    Br J Haematol. 2021;192:e7-e11.
    PubMed    


  230. MASON CC, Fiol CR, Baker MJ, Nadal-Melsio E, et al
    Identification of genetic targets in acute myeloid leukaemia for designing targeted therapy.
    Br J Haematol. 2021;192:137-145.
    PubMed     Abstract available


  231. FRISANCO OLIVEIRA A, Tansini A, Toledo TR, Balceiro R, et al
    Immunophenotypic characteristics of juvenile myelomonocytic leukaemia and their relation with the molecular subgroups of the disease.
    Br J Haematol. 2021;192:129-136.
    PubMed     Abstract available


  232. RADICH J
    Molecular testing of chronic myeloid leukaemia in low resource areas.
    Br J Haematol. 2021;192:28-32.
    PubMed     Abstract available


  233. DUAN W, Liu X, Jia J, Wang J, et al
    The loss or absence of minimal residual disease of <0.1% at any time after two cycles of consolidation chemotherapy in CBFB-MYH11-positive acute myeloid leukaemia indicates poor prognosis.
    Br J Haematol. 2021;192:265-271.
    PubMed     Abstract available


  234. MILOJKOVIC D, Cross NCP, Ali S, Byrne J, et al
    Real-world tyrosine kinase inhibitor treatment pathways, monitoring patterns and responses in patients with chronic myeloid leukaemia in the United Kingdom: the UK TARGET CML study.
    Br J Haematol. 2021;192:62-74.
    PubMed     Abstract available


    December 2020
  235. NAKAHATA S, Morishita K
    Commentary on: clinical significance of CD28 gene-related activating alterations in adult T-cell leukaemia/lymphoma.
    Br J Haematol. 2020 Dec 14. doi: 10.1111/bjh.17214.
    PubMed    


  236. NELSON ND, McMahon CM, El-Sharkawy Navarro F, Freyer CW, et al
    Rapid fluorescence in situ hybridisation optimises induction therapy for acute myeloid leukaemia.
    Br J Haematol. 2020;191:935-938.
    PubMed    


  237. CHEN J, Wang F, Fang J, Nie D, et al
    Dynamic evolution of ponatinib-resistant mutations in BCR-ABL1-positive leukaemias revealed by next-generation sequencing.
    Br J Haematol. 2020;191:e113-e116.
    PubMed    


  238. PARRY-JONES N, Joshi A, Forconi F, Dearden C, et al
    Guideline for diagnosis and management of hairy cell leukaemia (HCL) and hairy cell variant (HCL-V).
    Br J Haematol. 2020;191:730-737.
    PubMed    


  239. GANGAT N, Morsia E, Foran JM, Palmer JM, et al
    Venetoclax plus hypomethylating agent in blast-phase myeloproliferative neoplasm: preliminary experience with 12 patients.
    Br J Haematol. 2020;191:e120-e124.
    PubMed    


  240. MOORMAN AV, Schwab C, Winterman E, Hancock J, et al
    Adjuvant tyrosine kinase inhibitor therapy improves outcome for children and adolescents with acute lymphoblastic leukaemia who have an ABL-class fusion.
    Br J Haematol. 2020;191:844-851.
    PubMed     Abstract available


  241. MERYK A, Kropshofer G, Hutter J, Fritz J, et al
    Benefits of risk-adapted and mould-specific antifungal prophylaxis in childhood leukaemia.
    Br J Haematol. 2020;191:816-824.
    PubMed     Abstract available


  242. SIBAI H, Chen R, Liu X, Falcone U, et al
    Anticoagulation prophylaxis reduces venous thromboembolism rate in adult acute lymphoblastic leukaemia treated with asparaginase-based therapy.
    Br J Haematol. 2020;191:748-754.
    PubMed     Abstract available


  243. FRISCH A, Rowe JM, Ofran Y
    How we treat older patients with acute myeloid leukaemia.
    Br J Haematol. 2020;191:682-691.
    PubMed     Abstract available


    November 2020
  244. ZHANG X, Suo S, Wang J, Jin J, et al
    IDH1(R132S) -mutated acute lymphoblastic leukaemia resembles Burkitt lymphoma/leukaemia via activating MYC.
    Br J Haematol. 2020 Nov 21. doi: 10.1111/bjh.17199.
    PubMed    


  245. SAKAMOTO Y, Ishida T, Masaki A, Takeshita M, et al
    Clinical significance of CD28 gene-related activating alterations in adult T-cell leukaemia/lymphoma.
    Br J Haematol. 2020 Nov 18. doi: 10.1111/bjh.17211.
    PubMed     Abstract available


  246. MONDELLO P, Zelenetz AD
    Reshaping the therapeutic landscape of chronic lymphocytic leukaemia in the era of targeted therapy.
    Br J Haematol. 2020;191:326-328.
    PubMed    


  247. CHAGALUKA G, Schwalbe EC, Chakumatha E, Carey P, et al
    Challenges of starting treatment protocols for acute lymphoblastic leukaemia in a low-income setting - the Blantyre experience.
    Br J Haematol. 2020;191:e87-e90.
    PubMed    


  248. CASSADAY RD, Marks DI, DeAngelo DJ, Jabbour EJ, et al
    Impact of number of cycles on outcomes of patients with relapsed or refractory acute lymphoblastic leukaemia treated with inotuzumab ozogamicin.
    Br J Haematol. 2020;191:e77-e81.
    PubMed    


  249. TUEUR G, Lazarian G, Eclache V, Fleury C, et al
    Prevalence, distribution and predictive value of XPO1 mutation in a real-life chronic lymphocytic leukaemia cohort.
    Br J Haematol. 2020;191:e90-e94.
    PubMed    


  250. MATTSSON A, Sylvan SE, Asklid A, Wiggh J, et al
    Risk-adapted bendamustine + rituximab is a tolerable treatment alternative for elderly patients with chronic lymphocytic leukaemia: a regional real-world report on 141 consecutive Swedish patients.
    Br J Haematol. 2020;191:426-432.
    PubMed     Abstract available


  251. DERRIEUX C, Gish A, Caulier A, Grardel N, et al
    Shared clonal IGH rearrangement in BCP-ALL occurring after CLL: pitfalls and implications for MRD monitoring.
    Br J Haematol. 2020;191:506-509.
    PubMed    


  252. IRANI YD, Hughes A, Clarson J, Kok CH, et al
    Successful treatment-free remission in chronic myeloid leukaemia and its association with reduced immune suppressors and increased natural killer cells.
    Br J Haematol. 2020;191:433-441.
    PubMed     Abstract available


    October 2020
  253. HERISHANU Y, Levi S, Kamdjou T, Bornstein Y, et al
    Obinutuzumab in the treatment of autoimmune haemolytic anaemia and immune thrombocytopenia in patients with chronic lymphocytic leukaemia/small lymphocytic lymphoma.
    Br J Haematol. 2020 Oct 23. doi: 10.1111/bjh.17105.
    PubMed    


  254. FOX TA, Troy-Barnes E, Kirkwood AA, Chan WY, et al
    Clinical outcomes and risk factors for severe COVID-19 in patients with haematological disorders receiving chemo- or immunotherapy.
    Br J Haematol. 2020;191:194-206.
    PubMed     Abstract available


  255. CLARK RE
    Another set of guidelines for chronic myeloid leukaemia.
    Br J Haematol. 2020;191:147-149.
    PubMed    


  256. GILLEECE MH, Savani BN
    A stitch in time saves nine... MRD-based pre-emptive therapy.
    Br J Haematol. 2020;191:19-20.
    PubMed    


  257. BO A, Raiola AM, Gualandi F, Orengo G, et al
    Unintentional human leukocyte antigen-mismatched haematopoietic cell transplant: clinical course and root cause analysis.
    Br J Haematol. 2020;191:e35-e37.
    PubMed    


  258. MONTORO J, Chorao P, Quintero A, Roca J, et al
    Male genital GvHD: a hidden complication following haematopoietic stem cell transplantation.
    Br J Haematol. 2020;191:12.
    PubMed    


  259. SMITH G, Apperley J, Milojkovic D, Cross NCP, et al
    A British Society for Haematology Guideline on the diagnosis and management of chronic myeloid leukaemia.
    Br J Haematol. 2020;191:171-193.
    PubMed    


  260. MCCLURE BJ, Heatley SL, Rehn J, Breen J, et al
    High-risk B-cell acute lymphoblastic leukaemia presenting with hypereosinophilia and acquiring a novel PAX5 fusion on relapse.
    Br J Haematol. 2020;191:301-304.
    PubMed    


  261. RASHIDI A, Kaiser T, Ebadi M, Holtan SG, et al
    Circulating bacterial DNA and neutropenic fever during anti-leukaemia chemotherapy.
    Br J Haematol. 2020;191:e55-e58.
    PubMed    


  262. DONG S, Khedro T, Ward P, Dubeau L, et al
    First reported case of BRAF V600E mutation in T-cell prolymphocytic leukaemia.
    Br J Haematol. 2020;191:e52-e55.
    PubMed    


  263. KONG D, Qu C, Dai H, Li Z, et al
    CAR-T therapy bridging to allogeneic HSCT provides durable molecular remission of Ph(+) mixed phenotype acute leukaemia with minimal residual disease.
    Br J Haematol. 2020;191:e47-e49.
    PubMed    


  264. KHALIFE R, Montroy J, Grigor EJM, Fergusson DA, et al
    Building Canadian capacity for CAR-T cells in relapsed/refractory acute lymphoblastic leukaemia: a retrospective cohort study.
    Br J Haematol. 2020;191:e14-e19.
    PubMed    


  265. PAUL S, Jammal N, Akhave N, Aung PP, et al
    Atypical cases of necrotizing sweet syndrome in patients with myelodysplastic syndrome and acute myeloid leukaemia.
    Br J Haematol. 2020;191:e10-e13.
    PubMed    


  266. CERRANO M, Castella B, Lia G, Olivi M, et al
    Immunomodulatory and clinical effects of daratumumab in T-cell acute lymphoblastic leukaemia.
    Br J Haematol. 2020;191:e28-e32.
    PubMed    


  267. RYLAND GL, Barraclough A, Fong CY, Fleming S, et al
    Inotuzumab ozogamicin resistance associated with a novel CD22 truncating mutation in a case of B-acute lymphoblastic leukaemia.
    Br J Haematol. 2020;191:123-126.
    PubMed    


  268. ZABKIEWICZ J, Lazenby M, Edwards G, Bygrave CA, et al
    Combination of a mitogen-activated protein kinase inhibitor with the tyrosine kinase inhibitor pacritinib combats cell adhesion-based residual disease and prevents re-expansion of FLT3-ITD acute myeloid leukaemia.
    Br J Haematol. 2020;191:231-242.
    PubMed     Abstract available


  269. WANG J, Mou N, Yang Z, Li Q, et al
    Efficacy and safety of humanized anti-CD19-CAR-T therapy following intensive lymphodepleting chemotherapy for refractory/relapsed B acute lymphoblastic leukaemia.
    Br J Haematol. 2020;191:212-222.
    PubMed     Abstract available


  270. GANZEL C, Wang XV, Rowe JM, Richards SM, et al
    At three years, patients with acute lymphoblastic leukaemia are still at risk for relapse. Results of the international MRC UKALLXII/ECOG E2993 trial.
    Br J Haematol. 2020;191:37-43.
    PubMed     Abstract available


    September 2020
  271. ORF K, Rogosic S, Dexter D, Ancliff P, et al
    Remdesivir during induction chemotherapy for newly diagnosed paediatric acute lymphoblastic leukaemia with concomitant SARS-CoV-2 infection.
    Br J Haematol. 2020;190:e274-e276.
    PubMed    


  272. SILLA L
    Double-bright (CD56bright/CD16bright) natural killer cell adoptive immunotherapy for SARS-CoV-2.
    Br J Haematol. 2020;190:e322-e323.
    PubMed    


  273. NESR G, Koshy R, Foldes D, Kagdi H, et al
    Autoimmune haemolytic anaemia and a marked rise in the lymphocyte count associated with COVID-19 in a patient with treatment-naive chronic lymphocytic leukaemia: a case report.
    Br J Haematol. 2020;190:e326-e328.
    PubMed    


  274. SMOLEJ L
    Incidence and prognostic significance of serum immunoglobulins and paraproteins in patients with chronic lymphocytic leukaemia: another valuable piece of the puzzle.
    Br J Haematol. 2020;190:815-816.
    PubMed    


  275. EYRE TA
    Prognostication in Richter syndrome: context is everything.
    Br J Haematol. 2020;190:811-812.
    PubMed    


  276. CORBINGI A, Innocenti I, Tomasso A, Pasquale R, et al
    Monoclonal gammopathy and serum immunoglobulin levels as prognostic factors in chronic lymphocytic leukaemia.
    Br J Haematol. 2020;190:901-908.
    PubMed     Abstract available


  277. SHOUMARIYEH K, Hussung S, Niemoller C, Bleul S, et al
    Blastic transformation of BCR-ABL1 positive chronic myeloid leukaemia through acquisition of CBFB-MYH11 and mutant KIT.
    Br J Haematol. 2020;190:e339-e343.
    PubMed    


  278. DE PROPRIS MS, Intoppa S, Milani ML, Mariglia P, et al
    ROR1 is an accurate and reliable marker of minimal residual disease in chronic lymphocytic leukaemia.
    Br J Haematol. 2020;190:e346-e349.
    PubMed    


  279. SAITO Y, Makita S, Chinen S, Kito M, et al
    Acute megakaryoblastic leukaemia with t(1;22)(p13.3;q13.1)/RBM15-MKL1 in an adult patient following a non-mediastinal germ cell tumour.
    Br J Haematol. 2020;190:e329-e332.
    PubMed    


  280. BRECCIA M, Vignetti M, Annibali O, Cottone F, et al
    Younger age at diagnosis of acute promyelocytic leukaemia is associated with better long-term cognitive functioning.
    Br J Haematol. 2020;190:e304-e307.
    PubMed    


  281. FOX LC, Tan M, Brown AL, Arts P, et al
    A synonymous GATA2 variant underlying familial myeloid malignancy with striking intrafamilial phenotypic variability.
    Br J Haematol. 2020;190:e297-e301.
    PubMed    


  282. YAMANE T, Kawakami T, Sekiguchi N, Kobayashi J, et al
    High frequency of STAT3 gene mutations in T-cell receptor (TCR)gammadelta-type T-cell large granular lymphocytic leukaemia: implications for molecular diagnostics.
    Br J Haematol. 2020;190:e301-e304.
    PubMed    


  283. HANEKAMP D, Snel AN, Kelder A, Scholten WJ, et al
    Applicability and reproducibility of acute myeloid leukaemia stem cell assessment in a multi-centre setting.
    Br J Haematol. 2020;190:891-900.
    PubMed     Abstract available


  284. OFFNER F, Robak T, Janssens A, Govind Babu K, et al
    A five-year follow-up of untreated patients with chronic lymphocytic leukaemia treated with ofatumumab and chlorambucil: final analysis of the Complement 1 phase 3 trial.
    Br J Haematol. 2020;190:736-740.
    PubMed     Abstract available


  285. TURKINA A, Wang J, Mathews V, Saydam G, et al
    TARGET: a survey of real-world management of chronic myeloid leukaemia across 33 countries.
    Br J Haematol. 2020;190:869-876.
    PubMed     Abstract available


  286. VARGHESE AM, Sood N, Daniel SM
    Current pricing model for cancer drugs - is it 'Justum Pretium' for the developing world? Taking management of chronic lymphocytic leukaemia in India into consideration.
    Br J Haematol. 2020;190:e292-e294.
    PubMed    


  287. EL CHAER F, Ballen KK
    Treatment of acute leukaemia in adult Jehovah's Witnesses.
    Br J Haematol. 2020;190:696-707.
    PubMed     Abstract available


    August 2020
  288. RANGER A, Haji R, Kaczmarski R, Danga A, et al
    Interleukin-6 blockade treatment for COVID-19 associated cytokine release syndrome in a patient with poorly controlled chronic myeloid leukaemia.
    Br J Haematol. 2020;190:e128-e130.
    PubMed    


  289. PICIOCCHI A, Messina M, Soddu S, La Sala E, et al
    The COVID-19 pandemic and management of GIMEMA clinical trials: changes and challenges.
    Br J Haematol. 2020;190:e211-e214.
    PubMed    


  290. FARAH N, Burt R, Ibrahim AR, Baker R, et al
    Concerns about how to use established minimal residual disease monitoring in the treatment of NPM1-mutant acute myeloid leukaemia (AML) following reduced intensity chemotherapy protocols for AML given as a result of the COVID-19 pandemic.
    Br J Haematol. 2020;190:e208-e210.
    PubMed    


  291. CHOPRA J, Hiew HJ, Cumpstey A, Cagampang F, et al
    Successful treatment of chronic myelomonocytic leukaemia with hydroxycarbamide in a patient presenting with acute hypoxic respiratory failure due to COVID-19 pneumonia.
    Br J Haematol. 2020;190:e195-e198.
    PubMed    


  292. INNES AJ, Cook LB, Marks S, Bataillard E, et al
    Ruxolitinib for tocilizumab-refractory severe COVID-19 infection.
    Br J Haematol. 2020;190:e198-e200.
    PubMed    


  293. WILSON AJ, Troy-Barnes E, Subhan M, Clark F, et al
    Successful remission induction therapy with gilteritinib in a patient with de novo FLT3-mutated acute myeloid leukaemia and severe COVID-19.
    Br J Haematol. 2020;190:e189-e191.
    PubMed    


  294. FARMER I, Okikiolu J, Steel M, Wanniarachchi C, et al
    Acute promyelocytic leukaemia lying under the mask of COVID-19-a diagnostic and therapeutic conundrum.
    Br J Haematol. 2020;190:e248-e250.
    PubMed    


  295. LEISCH M, Greil R, Pleyer L
    IDO in MDS/AML disease progression and its role in resistance to azacitidine: a potential new drug target?
    Br J Haematol. 2020;190:314-317.
    PubMed    


  296. ANDREWS C, Maze D, Murphy T, Sibai H, et al
    Combination treatment with CPX-351 and midostaurin in patients with secondary acute myeloid leukaemia that are FLT3 mutated: three cases and review of literature.
    Br J Haematol. 2020;190:467-470.
    PubMed    


  297. ZHU J, Raimbault A, Sourdeau E, Maillon A, et al
    Holding on to the Matutes score while dropping FMC7: new opportunity from standardised approaches in multiparameter flow cytometry.
    Br J Haematol. 2020;190:e255-e258.
    PubMed    


  298. GLAVEY SV, Flanagan L, Bleach R, Kelly C, et al
    Secondary plasma cell leukaemia treated with single agent venetoclax.
    Br J Haematol. 2020;190:e242-e245.
    PubMed    


  299. CHOWDHURY A, Loaiza S, Yebra-Fernandez E, Nadal-Melsio E, et al
    An ex vivo investigation of interactions between primary acute myeloid leukaemia and mesenchymal stromal cells yields novel therapeutic targets.
    Br J Haematol. 2020;190:e236-e239.
    PubMed    


  300. FIEDLER W, Chromik J, Amberg S, Kebenko M, et al
    A Phase II study of selinexor plus cytarabine and idarubicin in patients with relapsed/refractory acute myeloid leukaemia.
    Br J Haematol. 2020;190:e169-e173.
    PubMed    


  301. NIE D, Zhang J, Xiong M, Wang F, et al
    Complete remission of refractory juvenile acute myeloid leukaemia with RUNX1-PRDM16 in Bloom syndrome after haematopoietic stem cell transplantation.
    Br J Haematol. 2020;190:e166-e169.
    PubMed    


  302. PETERLIN P, Cluzeau T, Jullien M, Ngo Nloga AM, et al
    Azacitidine in patients older than 80 years with acute myeloid leukaemia or myelodysplastic syndromes: a report on 115 patients.
    Br J Haematol. 2020;190:461-464.
    PubMed    


  303. LOKE J, Lowe DM, Miller LJ, Morton S, et al
    Supportive care in the management of patients with acute myeloid leukaemia: where are the research needs?
    Br J Haematol. 2020;190:311-313.
    PubMed    


  304. LEBLANC FR, Pearson JM, Tan SF, Cheon H, et al
    Sphingosine kinase-2 is overexpressed in large granular lymphocyte leukaemia and promotes survival through Mcl-1.
    Br J Haematol. 2020;190:405-417.
    PubMed     Abstract available


  305. WANG J, Lu R, Wu Y, Jia J, et al
    Detection of measurable residual disease may better predict outcomes than mutations based on next-generation sequencing in acute myeloid leukaemia with biallelic mutations of CEBPA.
    Br J Haematol. 2020;190:533-544.
    PubMed     Abstract available


  306. WILHELMSON AS, Porse BT
    CCAAT enhancer binding protein alpha (CEBPA) biallelic acute myeloid leukaemia: cooperating lesions, molecular mechanisms and clinical relevance.
    Br J Haematol. 2020;190:495-507.
    PubMed     Abstract available


  307. SAGLIO G, Gale RP
    Prospects for achieving treatment-free remission in chronic myeloid leukaemia.
    Br J Haematol. 2020;190:318-327.
    PubMed     Abstract available


  308. HERUDKOVA Z, Culen M, Folta A, Jeziskova I, et al
    Clonal hierarchy of main molecular lesions in acute myeloid leukaemia.
    Br J Haematol. 2020;190:562-572.
    PubMed     Abstract available


    July 2020
  309. GESTRICH CK, Sadri N, Sinno MG, Pateva I, et al
    Reciprocal ATP5L-KMT2A gene fusion in a paediatric B lymphoblastic leukaemia/lymphoma (B-ALL) patient.
    Br J Haematol. 2020 Jul 29. doi: 10.1111/bjh.17000.
    PubMed    


  310. BLENNERHASSETT R, Kwan J, Coyle L, Wong K, et al
    Adult B- and T-lymphoblastic lymphoma treated with a paediatric acute lymphoblastic leukaemia regimen have excellent outcomes-a short report from two Sydney centres.
    Br J Haematol. 2020 Jul 28. doi: 10.1111/bjh.16998.
    PubMed    


  311. BARNEA SLONIM L, Ma S, Behdad A, Chen Q, et al
    Pseudo-Richter transformation of chronic lymphocytic leukaemia/small lymphocytic lymphoma following ibrutinib interruption: a diagnostic pitfall.
    Br J Haematol. 2020 Jul 17. doi: 10.1111/bjh.16948.
    PubMed    


  312. YANG Y, Juskevicius R
    T-lymphoblastic leukaemia/lymphoma with rosettes and gland-like structures.
    Br J Haematol. 2020 Jul 7. doi: 10.1111/bjh.16929.
    PubMed    


  313. FOA R, Bonifacio M, Chiaretti S, Curti A, et al
    Philadelphia-positive acute lymphoblastic leukaemia (ALL) in Italy during the COVID-19 pandemic: a Campus ALL study.
    Br J Haematol. 2020;190:e3-e5.
    PubMed    


  314. DAY JW, Fox TA, Halsey R, Carpenter B, et al
    Interleukin-1 blockade with anakinra in acute leukaemia patients with severe COVID-19 pneumonia appears safe and may result in clinical improvement.
    Br J Haematol. 2020;190:e80-e83.
    PubMed    


  315. KRUG U, Berdel WE
    Smoking and AML - another piece in the puzzle.
    Br J Haematol. 2020;190:143.
    PubMed    


  316. MALAGOLA M, Bernardi S, Polverelli N, Russo D, et al
    Minimal residual disease monitoring in acute myeloid leukaemia: are we ready to move from bone marrow to peripheral blood?
    Br J Haematol. 2020;190:135-136.
    PubMed    


  317. BARON F, Savani BN
    Graft-versus-host-disease does not help acute lymphoblastic leukaemia patients with measurable residual disease.
    Br J Haematol. 2020;190:22-23.
    PubMed    


  318. ARMAND P, Murawski N, Molin D, Zain J, et al
    Pembrolizumab in relapsed or refractory Richter syndrome.
    Br J Haematol. 2020;190:e117-e120.
    PubMed    


  319. CALVO C, Cabannes-Hamy A, Adjaoud D, Bruno B, et al
    Inotuzumab ozogamicin compassionate use for French paediatric patients with relapsed or refractory CD22-positive B-cell acute lymphoblastic leukaemia.
    Br J Haematol. 2020;190:e53-e56.
    PubMed    


  320. KAUR U, Gambhir IS, Khare VR, Singh A, et al
    Delayed resistance to imatinib after 16 years of therapy in a patient with chronic myeloid leukaemia.
    Br J Haematol. 2020;190:e51-e53.
    PubMed    


  321. KRISTENSEN D, Nielsen LB, Roug AS, Kristensen TC, et al
    The prognostic effect of smoking status on intensively treated acute myeloid leukaemia - A Danish nationwide cohort study.
    Br J Haematol. 2020;190:236-243.
    PubMed     Abstract available


  322. REA B, Bailey NG
    Acute myeloid leukaemia with t(8;16)(p11.2;p13.3) and erythrophagocytosis.
    Br J Haematol. 2020;190:133.
    PubMed    


  323. JUUL-DAM KL, Ommen HB, Nyvold CG, Walter C, et al
    Measurable residual disease assessment by qPCR in peripheral blood is an informative tool for disease surveillance in childhood acute myeloid leukaemia.
    Br J Haematol. 2020;190:198-208.
    PubMed     Abstract available


  324. BENEFORTI L, Dander E, Bresolin S, Bueno C, et al
    Pro-inflammatory cytokines favor the emergence of ETV6-RUNX1-positive pre-leukemic cells in a model of mesenchymal niche.
    Br J Haematol. 2020;190:262-273.
    PubMed     Abstract available


  325. ZHOU YL, Wu LX, Peter Gale R, Wang ZL, et al
    Mutation topography and risk stratification for de novo acute myeloid leukaemia with normal cytogenetics and no nucleophosmin 1 (NPM1) mutation or Fms-like tyrosine kinase 3 internal tandem duplication (FLT3-ITD).
    Br J Haematol. 2020;190:274-283.
    PubMed     Abstract available


  326. ZHANG JM, Xu Y, Gale RP, Wu LX, et al
    DPEP1 expression promotes proliferation and survival of leukaemia cells and correlates with relapse in adults with common B cell acute lymphoblastic leukaemia.
    Br J Haematol. 2020;190:67-78.
    PubMed     Abstract available


    June 2020
  327. FAVRESSE J, Eucher C, Elsen M, Graux C, et al
    Unexpected kinetics of anti-SARS-CoV-2 total antibodies in two patients with chronic lymphocytic leukemia.
    Br J Haematol. 2020 Jun 17. doi: 10.1111/bjh.16954.
    PubMed     Abstract available


  328. YANG LH, Zhao Y, Maule J, Rapisardo S, et al
    T-lymphoblastic lymphoma and acute myeloid leukaemia transformed from myeloid neoplasm with eosinophilia: a divergent evolution of myeloid neoplasm with monosomy 7 but no detectable tyrosine kinase gene rearrangements designated by the WHO Classificat
    Br J Haematol. 2020 Jun 11. doi: 10.1111/bjh.16886.
    PubMed    


  329. ABRISQUETA P, Delgado J, Alcoceba M, Oliveira AC, et al
    Clinical outcome and prognostic factors of patients with Richter syndrome: real-world study of the Spanish Chronic Lymphocytic Leukemia Study Group (GELLC).
    Br J Haematol. 2020 Jun 9. doi: 10.1111/bjh.16748.
    PubMed     Abstract available


  330. LARSSON K, Mattsson M, Ebrahim F, Glimelius I, et al
    High prevalence and incidence of cardiovascular disease in chronic lymphocytic leukaemia: a nationwide population-based study.
    Br J Haematol. 2020 Jun 9. doi: 10.1111/bjh.16859.
    PubMed    


  331. BATALLER A, Onate G, Diaz-Beya M, Guijarro F, et al
    Acute myeloid leukemia with NPM1 mutation and favorable European LeukemiaNet category: outcome after preemptive intervention based on measurable residual disease.
    Br J Haematol. 2020 Jun 8. doi: 10.1111/bjh.16857.
    PubMed     Abstract available


  332. WILLAN J, King AJ, Djebbari F, Turner GDH, et al
    Assessing the impact of lockdown: Fresh challenges for the care of haematology patients in the COVID-19 pandemic.
    Br J Haematol. 2020;189:e224-e227.
    PubMed    


  333. SIENI E, Pegoraro F, Casini T, Tondo A, et al
    Favourable outcome of coronavirus disease 2019 in a 1-year-old girl with acute myeloid leukaemia and severe treatment-induced immunosuppression.
    Br J Haematol. 2020;189:e222-e224.
    PubMed    


  334. LANGERAK AW, Davi F, Stamatopoulos K
    Immunoglobulin heavy variable somatic hyper mutation status in chronic lymphocytic leukaemia: on the threshold of a new era?
    Br J Haematol. 2020;189:809-810.
    PubMed    


  335. STAHL M, Tallman MS
    Outcomes of allogeneic stem cell transplantation for patients with t(6:9) AML- A strong case for allogeneic stem cell transplantation in first complete remission.
    Br J Haematol. 2020;189:806-808.
    PubMed    


  336. RAEDLER J, Heyde S, Kolokythas M, Eichinger A, et al
    Venetoclax and decitabine for relapsed paediatric myelodysplastic syndrome-related acute myeloid leukaemia with complex aberrant karyotype after second stem cell transplantation.
    Br J Haematol. 2020;189:e251-e254.
    PubMed    


  337. DHAMI SPS, Tirincsi A, Baev D, Krawczyk J, et al
    Theranostic drug test incorporating the bone-marrow microenvironment can predict the clinical response of acute myeloid leukaemia to chemotherapy.
    Br J Haematol. 2020;189:e254-e258.
    PubMed    


  338. LI XY, Qian JJ, Yang M, Zhang Y, et al
    An oral, chemotherapy-free regimen (dasatinib plus prednisone) as induction and consolidation for adult patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia.
    Br J Haematol. 2020;189:e231-e234.
    PubMed    


  339. DE FIGUEIREDO AF, Land MGP, Ferreira GM, Mencalha A, et al
    Clinical and biological correlates of the expression of select Polycomb complex genes in Brazilian children with acute promyelocytic leukaemia.
    Br J Haematol. 2020;189:e245-e248.
    PubMed    


  340. WU X, Zhang J, Chen Q, Zhou L, et al
    Efficacy of venetoclax in combination with azacitidine followed by haploidentical transplantation in refractory acute myeloid leukaemia and mixed phenotype acute leukaemia.
    Br J Haematol. 2020;189:e200-e204.
    PubMed    


  341. GONG Z, Zhou T, Liu H, Tang G, et al
    Genotype-phenotype correlation of unusual BCR-ABL1 transcripts in Philadelphia chromosome-positive leukaemia.
    Br J Haematol. 2020;189:e207-e211.
    PubMed    


  342. ZHANG J, Wang Y, Li SQ, Fang L, et al
    Correction of Bcl-x splicing improves responses to imatinib in chronic myeloid leukaemia cells and mouse models.
    Br J Haematol. 2020;189:1141-1150.
    PubMed     Abstract available


  343. LADIKOU EE, Chevassut T, Pepper CJ, Pepper AG, et al
    Dissecting the role of the CXCL12/CXCR4 axis in acute myeloid leukaemia.
    Br J Haematol. 2020;189:815-825.
    PubMed     Abstract available


  344. RAPONI S, Ilari C, Della Starza I, Cappelli LV, et al
    Redefining the prognostic likelihood of chronic lymphocytic leukaemia patients with borderline percentage of immunoglobulin variable heavy chain region mutations.
    Br J Haematol. 2020;189:853-859.
    PubMed     Abstract available


  345. DIAZ-BEYA M, Labopin M, Maertens J, Alijurf M, et al
    Allogeneic stem cell transplantation in AML with t(6;9)(p23;q34);DEK-NUP214 shows a favourable outcome when performed in first complete remission.
    Br J Haematol. 2020;189:920-925.
    PubMed     Abstract available


  346. AL-ALI HK, Griesshammer M, Foltz L, Palumbo GA, et al
    Primary analysis of JUMP, a phase 3b, expanded-access study evaluating the safety and efficacy of ruxolitinib in patients with myelofibrosis, including those with low platelet counts.
    Br J Haematol. 2020;189:888-903.
    PubMed     Abstract available


  347. PATEL BJ, Barot SV, Kuzmanovic T, Kerr C, et al
    Distinctive and common features of moderate aplastic anaemia.
    Br J Haematol. 2020;189:967-975.
    PubMed     Abstract available


    May 2020
  348. THIBAUD S, Tremblay D, Bhalla S, Zimmerman B, et al
    Protective Role of BTK Inhibitors in Patients with Chronic Lymphocytic Leukemia and COVID-19.
    Br J Haematol. 2020 May 20. doi: 10.1111/bjh.16863.
    PubMed     Abstract available


  349. WU Y, Lin H, Xie Q, Chen Q, et al
    COVID-19 in a patient with pre-existing acute lymphoblastic leukemia.
    Br J Haematol. 2020 May 7. doi: 10.1111/bjh.16799.
    PubMed     Abstract available


  350. BALDACINI M, Pop R, Sattler L, Mauvieux L, et al
    Concomitant hemorrhagic syndrome and recurrent extensive arterial thrombosis in a patient with COVID-19 and acute promyelocytic leukemia.
    Br J Haematol. 2020 May 5. doi: 10.1111/bjh.16768.
    PubMed     Abstract available


  351. ANTELO G, Mangaonkar AA, Coltro G, Buradkar A, et al
    Response to erythropoiesis-stimulating agents in patients with WHO-defined myelodysplastic syndrome/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis (MDS/MPN-RS-T).
    Br J Haematol. 2020;189:e104-e108.
    PubMed    


  352. GU X, Saunthararajah Y
    Cytoplasmic dislocation of NPM1 and PU.1 in NPM1-mutated leukaemia is obscured by paraformaldehyde fixation.
    Br J Haematol. 2020;189:578-581.
    PubMed    


  353. GRIBBEN JG
    Do we need to analyse everything at diagnosis in chronic lymphocytic leukaemia?
    Br J Haematol. 2020;189:603-604.
    PubMed    


  354. RAYMOND LM, Funk T, Braziel RM, Fan G, et al
    Mast cell sarcoma with concurrent mast cell leukaemia.
    Br J Haematol. 2020;189:e160-e164.
    PubMed    


  355. ADELAIDE J, Cervera N, Guille A, Murati A, et al
    Gains of EPOR and ERG genes in adult erythroleukaemia.
    Br J Haematol. 2020;189:e174-e177.
    PubMed    


  356. INABA H, Cao X, Chang JY, Karol SE, et al
    Incidence of hip and knee osteonecrosis and their associations with bone mineral density in children with acute lymphoblastic leukaemia.
    Br J Haematol. 2020;189:e177-e181.
    PubMed    


  357. GIUSTI GNN, Jotta PY, Lopes CO, Ganazza MA, et al
    Test trial of spike-in immunoglobulin heavy-chain (IGH) controls for next generation sequencing quantification of minimal residual disease in acute lymphoblastic leukaemia.
    Br J Haematol. 2020;189:e150-e154.
    PubMed    


  358. ROBINSON SE, Harrison CN
    How we manage Philadelphia-negative myeloproliferative neoplasms in pregnancy.
    Br J Haematol. 2020;189:625-634.
    PubMed     Abstract available


  359. PRIETO-CONDE MI, Jimenez C, Garcia-Alvarez M, Ramos F, et al
    Identification of relapse-associated gene mutations by next-generation sequencing in low-risk acute myeloid leukaemia patients.
    Br J Haematol. 2020;189:718-730.
    PubMed     Abstract available


  360. ONECHA E, Ruiz-Heredia Y, Martinez-Cuadron D, Barragan E, et al
    Improving the prediction of acute myeloid leukaemia outcomes by complementing mutational profiling with ex vivo chemosensitivity.
    Br J Haematol. 2020;189:672-683.
    PubMed     Abstract available


  361. UDEN T, Bertaina A, Abrahamsson J, Ansari M, et al
    Outcome of children relapsing after first allogeneic haematopoietic stem cell transplantation for acute myeloid leukaemia: a retrospective I-BFM analysis of 333 children.
    Br J Haematol. 2020;189:745-750.
    PubMed     Abstract available


  362. MIKLOS U, Strugov V, Lewerin C, Grosicki S, et al
    Five-year survival follow-up of a phase III randomised trial comparing ofatumumab versus physicians' choice for bulky fludarabine-refractory chronic lymphocytic leukaemia: a short report.
    Br J Haematol. 2020;189:689-693.
    PubMed     Abstract available


  363. CICIARELLO M, Curti A
    Good news for acute myeloid leukaemia patients from the stroll niche?
    Br J Haematol. 2020;189:597-599.
    PubMed    


  364. CHEN X, Chen H
    BCR-ABL1-positive acute myeloid leukaemia relapsing as acute lymphoblastic leukaemia.
    Br J Haematol. 2020;189:591.
    PubMed    


  365. JIANG Y, Li Y, Cheng J, Ma J, et al
    Upregulation of AKR1C1 in mesenchymal stromal cells promotes the survival of acute myeloid leukaemia cells.
    Br J Haematol. 2020;189:694-706.
    PubMed     Abstract available


  366. ZHAO Y, Maule J, McCracken J, Li Y, et al
    Acute myeloid leukaemia with maturation demonstrates persistent disease with prominent megakaryoblastic differentiation 16 days following induction chemotherapy: an intra-myeloid lineage switch mediated by chemotherapy-induced clonal selection.
    Br J Haematol. 2020;189:e64-e67.
    PubMed    


  367. DULUCQ S, Astrugue C, Etienne G, Mahon FX, et al
    Risk of molecular recurrence after tyrosine kinase inhibitor discontinuation in chronic myeloid leukaemia patients: a systematic review of literature with a meta-analysis of studies over the last ten years.
    Br J Haematol. 2020;189:452-468.
    PubMed     Abstract available


  368. JORDAENS S, Cooksey L, Bonney S, Orchard L, et al
    Serum profiling identifies ibrutinib as a treatment option for young adults with B-cell acute lymphoblastic leukaemia.
    Br J Haematol. 2020;189:500-512.
    PubMed     Abstract available


  369. DELVECCHIO VS, Sana I, Mantione ME, Vilia MG, et al
    Interleukin-1 receptor-associated kinase 4 inhibitor interrupts toll-like receptor signalling and sensitizes chronic lymphocytic leukaemia cells to apoptosis.
    Br J Haematol. 2020;189:475-488.
    PubMed     Abstract available


  370. MARAJ A, MacEneaney O, Doyle B, Quinn J, et al
    Lysozyme-induced nephropathy: a rare manifestation of chronic myelomonocytic leukaemia.
    Br J Haematol. 2020;189:393.
    PubMed    


  371. LINCH DC, Hills RK, Burnett AK, Gale RE, et al
    The clinical impact of mutant DNMT3A R882 variant allele frequency in acute myeloid leukaemia.
    Br J Haematol. 2020;189:e81-e86.
    PubMed    


  372. MANOUSOPOULOU A, Wang LD
    ALL the comforts of homing: lymphoblasts find cerebrospinal fluid inhospitable without meningeal cell contact.
    Br J Haematol. 2020;189:395-397.
    PubMed    


  373. VAN DER STRATEN L, Levin MD, Visser O, Posthuma EFM, et al
    Survival continues to increase in chronic lymphocytic leukaemia: a population-based analysis among 20 468 patients diagnosed in the Netherlands between 1989 and 2016.
    Br J Haematol. 2020;189:574-577.
    PubMed    


  374. BASILE P, Jonart LM, Ebadi M, Johnson K, et al
    The meninges enhance leukaemia survival in cerebral spinal fluid.
    Br J Haematol. 2020;189:513-517.
    PubMed     Abstract available


  375. KLOOS R, van der Sluis IM, Mastrobattista E, Hennink W, et al
    Acute lymphoblastic leukaemia patients treated with PEGasparaginase develop antibodies to PEG and the succinate linker.
    Br J Haematol. 2020;189:442-451.
    PubMed     Abstract available


    April 2020
  376. AOKI T, Takahashi H, Tanaka S, Shiba N, et al
    Predisposition to prolonged neutropenia after chemotherapy for paediatric acute myeloid leukaemia is associated with better prognosis in the Japanese Paediatric Leukaemia/Lymphoma Study Group AML-05 study.
    Br J Haematol. 2020 Apr 26. doi: 10.1111/bjh.16656.
    PubMed     Abstract available


  377. FUSTER JL, Molinos-Quintana A, Fuentes C, Fernandez JM, et al
    Blinatumomab and inotuzumab for B cell precursor acute lymphoblastic leukaemia in children: a retrospective study from the Leukemia Working Group of the Spanish Society of Pediatric Hematology and Oncology (SEHOP).
    Br J Haematol. 2020 Apr 21. doi: 10.1111/bjh.16647.
    PubMed     Abstract available


  378. COGLE CR, Collins B, Turner D, Pettiford LC, et al
    Safety, feasibility and preliminary efficacy of single agent combretastatin A1 diphosphate (OXi4503) in patients with relapsed or refractory acute myeloid leukemia or myelodysplastic syndromes.
    Br J Haematol. 2020 Apr 1. doi: 10.1111/bjh.16629.
    PubMed    


  379. DHOLARIA B, Savani BN
    Allogeneic haematopoietic cell transplantation after CAR T-cell therapy: safe, effective and contentious.
    Br J Haematol. 2020;189:21-23.
    PubMed    


  380. BERTOLI S, Rieu JB, Recher C, Vergez F, et al
    Large granular lymphocytosis during quizartinib therapy.
    Br J Haematol. 2020;189:7.
    PubMed    


  381. EBADI M, Beckman AK, Yohe SL, Rashidi A, et al
    It's all in the film.
    Br J Haematol. 2020;189:8.
    PubMed    


  382. OSTERROOS A, Eriksson A, Antunovic P, Cammenga J, et al
    Real-world data on treatment patterns and outcomes of hypomethylating therapy in patients with newly diagnosed acute myeloid leukaemia aged >/= 60 years.
    Br J Haematol. 2020;189:e13-e16.
    PubMed    


  383. GODWIN CD, Bates OM, Garling EE, Beddoe ME, et al
    The Bruton's tyrosine kinase inhibitor ibrutinib abrogates bispecific antibody-mediated T-cell cytotoxicity.
    Br J Haematol. 2020;189:e9-e13.
    PubMed    


  384. XU X, Zeng Z, Huo L, Liu H, et al
    High expression of myocyte enhancer factor 2C predicts poor prognosis for adult acute myeloid leukaemia with normal karyotype.
    Br J Haematol. 2020;189:e23-e27.
    PubMed    


  385. ZHANG Y, Chen H, Song Y, Tan X, et al
    Chimeric antigens receptor T cell therapy as a bridge to haematopoietic stem cell transplantation for refractory/ relapsed B-cell acute lymphomalastic leukemia.
    Br J Haematol. 2020;189:146-152.
    PubMed     Abstract available


  386. ROESSNER PM, Hanna BS, Ozturk S, Schulz R, et al
    TBET-expressing Th1 CD4(+) T cells accumulate in chronic lymphocytic leukaemia without affecting disease progression in Emicro-TCL1 mice.
    Br J Haematol. 2020;189:133-145.
    PubMed     Abstract available


  387. WANG Y, Liu QF, Wu DP, Xu LP, et al
    Improved survival after offspring donor transplant compared with older aged-matched siblings for older leukaemia patients.
    Br J Haematol. 2020;189:153-161.
    PubMed     Abstract available


  388. YANG RY, Yang CX, Lang XP, Duan LJ, et al
    Identification of a novel RUNX1-TACC1 fusion transcript in acute myeloid leukaemia.
    Br J Haematol. 2020;189:e52-e56.
    PubMed    


  389. DO YR, Kwak JY, Kim JA, Kim HJ, et al
    Long-term data from a phase 3 study of radotinib versus imatinib in patients with newly diagnosed, chronic myeloid leukaemia in the chronic phase (RERISE).
    Br J Haematol. 2020;189:303-312.
    PubMed     Abstract available


  390. ROSSOFF J, Huynh V, Rau RE, Macy ME, et al
    Experience with ponatinib in paediatric patients with leukaemia.
    Br J Haematol. 2020;189:363-368.
    PubMed     Abstract available


  391. AWADA H, Mahfouz RZ, Durrani J, Kishtagari A, et al
    Large granular lymphocytic leukaemia after solid organ and haematopoietic stem cell transplantation.
    Br J Haematol. 2020;189:318-322.
    PubMed     Abstract available


  392. FRAZZI R, Bizzarri V, Albertazzi L, Cusenza VY, et al
    Droplet digital PCR is a sensitive tool for the detection of TP53 deletions and point mutations in chronic lymphocytic leukaemia.
    Br J Haematol. 2020;189:e49-e52.
    PubMed    


  393. BANKAR A, Korula A, Kulkarni UP, Devasia AJ, et al
    Resource utilization and cost effectiveness of treating acute promyelocytic leukaemia using generic arsenic trioxide.
    Br J Haematol. 2020;189:269-278.
    PubMed     Abstract available


  394. PIETTE C, Suciu S, Bertrand Y, Uyttebroeck A, et al
    Long-term outcome evaluation of medium/high risk acute lymphoblastic leukaemia children treated with or without cranial radiotherapy in the EORTC 58832 randomized study.
    Br J Haematol. 2020;189:351-362.
    PubMed     Abstract available


    March 2020
  395. TOUW IP, Sanders MA
    Mutant allelic burden in acute myeloid leukaemia: Why bother?
    Br J Haematol. 2020;188:817-818.
    PubMed    


  396. RICHARDSON AI, Skikne BS, Woodroof J
    Chronic myeloid leukaemia, BCR-ABL1-positive, in accelerated phase with marked eosinophilia with eosinophil atypia.
    Br J Haematol. 2020;188:599.
    PubMed    


  397. RADIA DH, Green A, Oni C, Moonim M, et al
    The clinical and pathological panoply of systemic mastocytosis.
    Br J Haematol. 2020;188:623-640.
    PubMed     Abstract available


  398. XUE YJ, Suo P, Huang XJ, Lu AD, et al
    Superior survival of unmanipulated haploidentical haematopoietic stem cell transplantation compared with intensive chemotherapy as post-remission treatment for children with very high-risk philadelphia chromosome negative B-cell acute lymphoblastic le
    Br J Haematol. 2020;188:757-767.
    PubMed     Abstract available


  399. PALOMO L, Ibanez M, Abaigar M, Vazquez I, et al
    Spanish Guidelines for the use of targeted deep sequencing in myelodysplastic syndromes and chronic myelomonocytic leukaemia.
    Br J Haematol. 2020;188:605-622.
    PubMed     Abstract available


  400. KNOFLER R, Lange BS, Paul F, Tiebel O, et al
    Bleeding signs due to acquired von Willebrand syndrome at diagnosis of chronic myeloid leukaemia in children.
    Br J Haematol. 2020;188:701-706.
    PubMed     Abstract available


  401. KIM YA, Ju HY, Park HJ, Lee NY, et al
    Outcomes of acute lymphoblastic leukaemia in adolescent and young adult Korean patients.
    Br J Haematol. 2020;188:740-744.
    PubMed     Abstract available


  402. CUCCHI DGJ, Bachas C, Klein K, Huttenhuis S, et al
    TP53 mutations and relevance of expression of TP53 pathway genes in paediatric acute myeloid leukaemia.
    Br J Haematol. 2020;188:736-739.
    PubMed     Abstract available


  403. ZHAO C, Jia B, Wang M, Schell TD, et al
    Multi-dimensional analysis identifies an immune signature predicting response to decitabine treatment in elderly patients with AML.
    Br J Haematol. 2020;188:674-684.
    PubMed     Abstract available


  404. CHIN-YEE B, Sadikovic B, Chin-Yee IH
    Genomic data in prognostic models-what is lost in translation? The case of deletion 17p and mutant TP53 in chronic lymphocytic leukaemia.
    Br J Haematol. 2020;188:652-660.
    PubMed     Abstract available


  405. GIONA F, Malaspina F, Putti MC, Ladogana S, et al
    Results and outcome of intermittent imatinib (ON/OFF schedule) in children and adolescents with chronic myeloid leukaemia.
    Br J Haematol. 2020;188:e101-e105.
    PubMed    


  406. GAUR V, Chaudhary S, Tyagi A, Agarwal S, et al
    Dysregulation of miRNA expression and their prognostic significance in paediatric cytogenetically normal acute myeloid leukaemia.
    Br J Haematol. 2020;188:e90-e94.
    PubMed    


  407. VAN DER STRATEN L, Levin MD, Visser O, Blijlevens NMA, et al
    The effectiveness of ibrutinib in chronic lymphocytic leukaemia: a nationwide, population-based study in the Netherlands.
    Br J Haematol. 2020;188:e109-e112.
    PubMed    


  408. GRIBBEN JG
    Practical management of tumour lysis syndrome in venetoclax-treated patients with chronic lymphocytic leukaemia.
    Br J Haematol. 2020;188:844-851.
    PubMed     Abstract available


  409. ZHOU C, Zhuang Y, Lin X, Michelson AD, et al
    Changes in neurocognitive function and central nervous system structure in childhood acute lymphoblastic leukaemia survivors after treatment: a meta-analysis.
    Br J Haematol. 2020;188:945-961.
    PubMed     Abstract available


  410. HOLTZMAN NG, El Chaer F, Baer MR, Ali O, et al
    Peripheral blood blast rate of clearance is an independent predictor of clinical response and outcomes in acute myeloid leukaemia.
    Br J Haematol. 2020;188:881-887.
    PubMed     Abstract available


  411. ELSTON L, Fegan C, Hills R, Hashimdeen SS, et al
    Increased frequency of CD4(+) PD-1(+) HLA-DR(+) T cells is associated with disease progression in CLL.
    Br J Haematol. 2020;188:872-880.
    PubMed     Abstract available


  412. EYRE TA, Roeker LE, Fox CP, Gohill SH, et al
    The efficacy and safety of venetoclax therapy in elderly patients with relapsed, refractory chronic lymphocytic leukaemia.
    Br J Haematol. 2020;188:918-923.
    PubMed     Abstract available


  413. LINCH DC, Hills RK, Burnett AK, Russell N, et al
    Analysis of the clinical impact of NPM1 mutant allele burden in a large cohort of younger adult patients with acute myeloid leukaemia.
    Br J Haematol. 2020;188:852-859.
    PubMed     Abstract available


    February 2020
  414. DALAL NH, Dores GM, Curtis RE, Linet MS, et al
    Cause-specific mortality in individuals with lymphoplasmacytic lymphoma/Waldenstrom macroglobulinaemia, 2000-2016.
    Br J Haematol. 2020 Feb 23. doi: 10.1111/bjh.16492.
    PubMed     Abstract available


  415. MONDELAERS V, Ferster A, Uyttebroeck A, Brichard B, et al
    Prospective, real-time monitoring of pegylated Escherichia coli and Erwinia asparaginase therapy in childhood acute lymphoblastic leukaemia and non-Hodgkin lymphoma in Belgium.
    Br J Haematol. 2020 Feb 14. doi: 10.1111/bjh.16495.
    PubMed     Abstract available


  416. MATSUO T, Ooi J, Tashiro H, Saito S, et al
    A major break of cord blood bag.
    Br J Haematol. 2020;188:e42-e43.
    PubMed    


  417. HOCKINGS C, Gohil S, Dowse R, Hoade Y, et al
    In trans early mosaic mutational escape and novel phenotypic features of germline SAMD9 mutation.
    Br J Haematol. 2020;188:e53-e57.
    PubMed    


  418. NILSSON MS, Hallner A, Brune M, Nilsson S, et al
    Complete remission after the first cycle of induction chemotherapy determines the clinical efficacy of relapse-preventive immunotherapy in acute myeloid leukaemia.
    Br J Haematol. 2020;188:e49-e53.
    PubMed    


  419. GURNEY M, Krawczyk J, Paz Nunez YE
    Megakaryocyte emperipolesis in B-lymphoblastic leukaemia.
    Br J Haematol. 2020;188:348.
    PubMed    


  420. CAPITANO M, Capo-Chichi JM, Minden MD, Chang H, et al
    Mixed phenotype acute leukaemia with predominant myeloid blasts and a small subset of B/myeloid blasts shares the same mutation profile.
    Br J Haematol. 2020;188:e60-e63.
    PubMed    


  421. BROWN P, Zugmaier G, Gore L, Tuglus CA, et al
    Day 15 bone marrow minimal residual disease predicts response to blinatumomab in relapsed/refractory paediatric B-ALL.
    Br J Haematol. 2020;188:e36-e39.
    PubMed    


  422. DA COSTA VEF, de Oliveira RD, Traina F, Chahud F, et al
    Co-occurrence of BCR-ABL1-positive chronic myeloid leukaemia and CALR-mutated essential thrombocythaemia.
    Br J Haematol. 2020;188:e21-e23.
    PubMed    


  423. SHAHSWAR R, Beutel G, Klement P, Rehberg A, et al
    FLA-IDA salvage chemotherapy combined with a seven-day course of venetoclax (FLAVIDA) in patients with relapsed/refractory acute leukaemia.
    Br J Haematol. 2020;188:e11-e15.
    PubMed    


  424. BARON F, Labopin M, Savani BN, Beohou E, et al
    Graft-versus-host disease and graft-versus-leukaemia effects in secondary acute myeloid leukaemia: a retrospective, multicentre registry analysis from the Acute Leukaemia Working Party of the EBMT.
    Br J Haematol. 2020;188:428-437.
    PubMed     Abstract available


  425. HARA Y, Shiba N, Yamato G, Ohki K, et al
    Patients aged less than 3 years with acute myeloid leukaemia characterize a molecularly and clinically distinct subgroup.
    Br J Haematol. 2020;188:528-539.
    PubMed     Abstract available


  426. HANSEN MC, Haferlach T, Nyvold CG
    A decade with whole exome sequencing in haematology.
    Br J Haematol. 2020;188:367-382.
    PubMed     Abstract available


    January 2020

  427. The Management of Acute Leukaemia in Adults.
    Br J Haematol. 2020;188:10-28.
    PubMed    


  428. DEROLF A, Juliusson G, Benson L, Floisand Y, et al
    Decreasing early mortality in acute myeloid leukaemia in Sweden 1997-2014: improving performance status is a major contributing factor.
    Br J Haematol. 2020;188:187-191.
    PubMed    


  429. OLIAI C, Schiller G
    How to address second and therapy-related acute myelogenous leukaemia.
    Br J Haematol. 2020;188:116-128.
    PubMed     Abstract available


  430. CHARROT S, Armes H, Rio-Machin A, Fitzgibbon J, et al
    AML through the prism of molecular genetics.
    Br J Haematol. 2020;188:49-62.
    PubMed     Abstract available


  431. HILLS RK
    Evaluating sixty years of UK trials research in acute myeloid leukaemia: lessons for trial design, past, present and future.
    Br J Haematol. 2020;188:29-35.
    PubMed     Abstract available


  432. PAUL S, Rausch CR, Jabbour EJ
    The face of remission induction.
    Br J Haematol. 2020;188:101-115.
    PubMed     Abstract available


  433. BURNETT AK, Hills RK, Russell N
    Twenty five years of UK trials in acute myeloid leukaemia: what have we learned?
    Br J Haematol. 2020;188:86-100.
    PubMed    


  434. HOKLAND P
    AML - a signature disease in haematology.
    Br J Haematol. 2020;188:7.
    PubMed    


  435. LOKE J, Malladi R, Moss P, Craddock C, et al
    The role of allogeneic stem cell transplantation in the management of acute myeloid leukaemia: a triumph of hope and experience.
    Br J Haematol. 2020;188:129-146.
    PubMed     Abstract available


  436. MO X, Chen H
    Acute promyelocytic leukaemia with myeloperoxidase-negative rectangular inclusions.
    Br J Haematol. 2020;188:8.
    PubMed    


  437. HAFERLACH T, Schmidts I
    The power and potential of integrated diagnostics in acute myeloid leukaemia.
    Br J Haematol. 2020;188:36-48.
    PubMed     Abstract available


  438. GARCIA SPEZZA E, Brethon B, Petit A, Mazingue F, et al
    Tolerance to arsenic trioxide combined with all-trans-retinoic acid in children with acute promyelocytic leukaemia in France.
    Br J Haematol. 2020;188:170-173.
    PubMed    


  439. GHOSH A, Barba P, Perales MA
    Checkpoint inhibitors in AML: are we there yet?
    Br J Haematol. 2020;188:159-167.
    PubMed     Abstract available


  440. JONES L, McCarthy P, Bond J
    Epigenetics of paediatric acute myeloid leukaemia.
    Br J Haematol. 2020;188:63-76.
    PubMed     Abstract available


  441. GHANNAM J, Dillon LW, Hourigan CS
    Next-generation sequencing for measurable residual disease detection in acute myeloid leukaemia.
    Br J Haematol. 2020;188:77-85.
    PubMed     Abstract available


  442. WANG T, Wang Z, Zhang L, Wen L, et al
    Identification of a novel TFG-FGFR1 fusion gene in an acute myeloid leukaemia patient with t(3;8)(q12;p11).
    Br J Haematol. 2020;188:177-181.
    PubMed    


  443. BARRETT AJ
    Acute myeloid leukaemia and the immune system: implications for immunotherapy.
    Br J Haematol. 2020;188:147-158.
    PubMed     Abstract available


  444. PIANIGIANI G, Betti C, Bigerna B, Rossi R, et al
    PU.1 subcellular localization in acute myeloid leukaemia with mutated NPM1.
    Br J Haematol. 2020;188:184-187.
    PubMed    


  445. JIANG G, Atenafu EG, Capo-Chichi JM, Minden MD, et al
    Prognostic relevance of CD123 expression in adult AML with normal karyotype.
    Br J Haematol. 2020;188:181-184.
    PubMed    


  446. ESPARZA S, Muluneh B, Galeotti J, Matson M, et al
    Venetoclax-induced tumour lysis syndrome in acute myeloid leukaemia.
    Br J Haematol. 2020;188:173-177.
    PubMed    


  447. YIN J, Zhu S, Luo Y, Lin Z, et al
    Acute myeloid leukaemia with Auer rods within pseudo-Chediak-Higashi granules.
    Br J Haematol. 2020;188:9.
    PubMed    


  448. KATAGIRI S, Gotoh A, Ohyashiki K
    Very late relapse with rapid BCR-ABL1 elevation after more than seven years of treatment-free remission with undetectable molecular residual disease in chronic myeloid leukaemia.
    Br J Haematol. 2020;188:332-334.
    PubMed    


  449. RAFEI H, Kantarjian HM, Jabbour EJ
    Targeted therapy paves the way for the cure of acute lymphoblastic leukaemia.
    Br J Haematol. 2020;188:207-223.
    PubMed     Abstract available


    November 2019
  450. ROSADAS C, Puccioni-Sohler M, Oliveira ACP, Casseb J, et al
    Adult T-cell leukaemia/lymphoma in Brazil: A rare disease or rarely diagnosed?
    Br J Haematol. 2019 Nov 19. doi: 10.1111/bjh.16318.
    PubMed    


    October 2019
  451. NYLAND SB, Feith DJ, Poss M, Olson TL, et al
    Retroviral sero-reactivity in LGL leukaemia patients and family members.
    Br J Haematol. 2019 Oct 14. doi: 10.1111/bjh.16223.
    PubMed     Abstract available


    July 2019
  452. FERRETTI A, Baldacci E, Miulli E, Canichella M, et al
    Thrombopoietin receptor agonists to control immune thrombocytopenia in patients with active lymphoma.
    Br J Haematol. 2019 Jul 31. doi: 10.1111/bjh.16114.
    PubMed    


  453. DOMINGUEZ-PINILLA N, Martinez-Zamorano E, Campos-Martin Y, Algara Plana P, et al
    Paediatric-type nodal follicular lymphoma in a child diagnosed with chronic myeloid leukaemia.
    Br J Haematol. 2019 Jul 8. doi: 10.1111/bjh.16089.
    PubMed    


    June 2019
  454. SAKAMOTO K, Shiba N, Deguchi T, Kiyokawa N, et al
    Negative CD19 expression is associated with inferior relapse-free survival in children with RUNX1-RUNX1T1-positive acute myeloid leukaemia: results from the Japanese Paediatric Leukaemia/Lymphoma Study Group AML-05 study.
    Br J Haematol. 2019 Jun 27. doi: 10.1111/bjh.16080.
    PubMed     Abstract available


    May 2019
  455. KHOGEER H, Rahman H, Jain N, Angelova EA, et al
    Early T precursor acute lymphoblastic leukaemia/lymphoma shows differential immunophenotypic characteristics including frequent CD33 expression and in vitro response to targeted CD33 therapy.
    Br J Haematol. 2019 May 22. doi: 10.1111/bjh.15960.
    PubMed     Abstract available


  456. TOYODA K, Tsukasaki K, Machida R, Kadota T, et al
    Possibility of a risk-adapted treatment strategy for untreated aggressive adult T-cell leukaemia-lymphoma (ATL) based on the ATL prognostic index: a supplementary analysis of the JCOG9801.
    Br J Haematol. 2019 May 16. doi: 10.1111/bjh.15950.
    PubMed     Abstract available


    February 2019
  457. KHASHAB T, Hagemeister F, Romaguera JE, Fanale MA, et al
    Long-term overall- and progression-free survival after pentostatin, cyclophosphamide and rituximab therapy for indolent non-Hodgkin lymphoma.
    Br J Haematol. 2019 Feb 28. doi: 10.1111/bjh.15814.
    PubMed     Abstract available


  458. BURKHARDT B, Hermiston ML
    Lymphoblastic lymphoma in children and adolescents: review of current challenges and future opportunities.
    Br J Haematol. 2019 Feb 27. doi: 10.1111/bjh.15793.
    PubMed     Abstract available


  459. MIYAMURA T, Moritake H, Nakayama H, Tanaka S, et al
    Clinical and biological features of paediatric acute myeloid leukaemia (AML) with primary induction failure in the Japanese Paediatric Leukaemia/Lymphoma Study Group AML-05 study.
    Br J Haematol. 2019 Feb 19. doi: 10.1111/bjh.15799.
    PubMed     Abstract available


  460. O'REILLY MA, Govender D, Kirkwood AA, Vora A, et al
    The incidence of invasive fungal infections in children, adolescents and young adults with acute lymphoblastic leukaemia/lymphoma treated with the UKALL2011 protocol: a multicentre retrospective study.
    Br J Haematol. 2019 Feb 15. doi: 10.1111/bjh.15798.
    PubMed    


    January 2019
  461. BATALLER A, Combalia A, Garcia-Herrera A, Estrach T, et al
    Isolated cutaneous lymphomatous form of adult T-cell leukaemia/lymphoma.
    Br J Haematol. 2019 Jan 6. doi: 10.1111/bjh.15744.
    PubMed    


    August 2018
  462. SU C, Bai HX, Xiao R
    HTLV-1 status should be recorded in cases of T cell lymphomas/lymphoproliferative disorders - cases of adult T cell leukaemia lymphoma masquerading as other T cell lymphomas/lymphoproliferative disorders could explain some of the apparent ethnic dispa
    Br J Haematol. 2018 Aug 3. doi: 10.1111/bjh.15526.
    PubMed    


  463. LO BELLO G, Naresh KN
    HTLV-1 status should be recorded in cases of T cell lymphomas/lymphoproliferative disorders - cases of adult T cell leukaemia lymphoma masquerading as other T cell lymphomas/lymphoproliferative disorders could explain some apparent ethnic disparities.
    Br J Haematol. 2018 Aug 3. doi: 10.1111/bjh.15527.
    PubMed    


    July 2018
  464. AILAWADHI S, Dholaria BR, Khurana S, Sher T, et al
    Outcomes of patients with simultaneous diagnosis of chronic lymphocytic leukaemia/small lymphocytic lymphoma and multiple myeloma.
    Br J Haematol. 2018 Jul 5. doi: 10.1111/bjh.15458.
    PubMed    


Thank you for your interest in scientific medicine.


AMEDEO Leukemia is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: